US3219533A - Aerosol solid medicament in propellant and low-level ethanol avoiding higher-level ethanol dispersed-solid reflocculation - Google Patents

Aerosol solid medicament in propellant and low-level ethanol avoiding higher-level ethanol dispersed-solid reflocculation Download PDF

Info

Publication number
US3219533A
US3219533A US241022A US24102262A US3219533A US 3219533 A US3219533 A US 3219533A US 241022 A US241022 A US 241022A US 24102262 A US24102262 A US 24102262A US 3219533 A US3219533 A US 3219533A
Authority
US
United States
Prior art keywords
medicament
ethanol
propellant
solid
compositions
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
US241022A
Inventor
John D Mullins
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck and Co Inc
Original Assignee
Merck and Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to BE629985D priority Critical patent/BE629985A/xx
Priority to NL289785D priority patent/NL289785A/xx
Application filed by Merck and Co Inc filed Critical Merck and Co Inc
Priority to US241022A priority patent/US3219533A/en
Priority to GB8798/63A priority patent/GB1018125A/en
Priority to DE19631492015 priority patent/DE1492015A1/en
Priority to FR932382A priority patent/FR1381252A/en
Application granted granted Critical
Publication of US3219533A publication Critical patent/US3219533A/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]

Definitions

  • compositions of this invention are substantially anhydrous suspensions or dispersions comprised essentially of a solid medicament uniformly dispersed or suspended throughout a substantially anhydrous liquid carrier comprised essentially of a non-toxic propellant and ethanol.
  • compositions of this invention are utilized for inhalation therapy there is obtained greater deposition and retention of the medicated particles in that region of the bronchial tree where it is optimally utilized.
  • some drugs such as the anti-inflammatory steroids, 8.
  • compositions of the present invention are also particularly useful for the systemic treatment of various diseases of the body which have heretofore been treated by parenteral administration of antibiotics and other medicaments such as insulin, adrenaline and triodothyronine.
  • antibiotics and other medicaments such as insulin, adrenaline and triodothyronine.
  • employing insulin as the medicament diabetes and other diseases which respond to insulin therapy, may be treated by inhalation therapy utilizing the compositions of this invention.
  • the treatment of such diseases by inhalation therapy obviates the need for administering the medicament via the parenteral route which is often discomforting to the patient.
  • the treatment of such diseases by inhalation therapy utilizing the compositions of this invention minimizes or eliminates certain of the classic side effects associated with parenteral administration, particularly intravenous injection.
  • compositions of the present invention are also particularly useful for ophthalmic therapy.
  • medicaments are normally applied to the eye either in the form of aqueous suspensions or solutions or as ointments.
  • the medicament is applied by dropper or eye cup whereas with the latter, application is made by pressing a small amount of ointment from a tube around the area of the eyelid which is then mechanically spread by movement of the eye itself.
  • Both methods present considerable problems, especially for self-medication.
  • accurate positioning is diflicult and the application is often wasteful and unsightly.
  • Furthemore utilizing these methods and compositions, the drug is administered to the eye by direct impact which may give rise to irritation.
  • the self-propelling medicament compositions of this invention can be self-applied more readily with appreciably less waste of the drug and without leaving any unsightly appearance as is the case with ophthalmic ointments.
  • the self-propelled compositions of the present invention provide for the administration of the drug to the eye as a fine mist, thereby substantially eliminating the irritation and waste often resulting when the drug is administered by conventional means.
  • the liquid carrier employed in the novel compositions of this invention is com-prised essentially of a mixture of a non-toxic liquid propellant and ethanol.
  • the propellant which constitutes the major portion of the carrier, should be non-toxic, have a vapor pressure between about 15 and pounds, and preferably between about 35 and 40 pounds per square inch gauge at 70 F., and be completely miscible with ethanol.
  • the propellants having the above characteristics are the fluorinated or fluorochlorinated lower saturated aliphatic hydrocarbons.
  • the preferred propellants of this type are the halogenated alkanes containing not more than two carbon atoms and at least one fluorine atoms.
  • trichloromonofluoromethane trichloromonofluoromethane, dichlorodifluoromethane, monochlorotrifluoromethane, dichloromonofluoromethane and 1,2-dichloro-1,1,2,2-tetrafiuoroethane.
  • Freon trichloromonofluoromethane, dichlorodifluoromethane, monochlorotrifluoromethane, dichloromonofluoromethane and 1,2-dichloro-1,1,2,2-tetrafiuoroethane.
  • fluorinated or fluorochlorinated lower saturatedaliphatic hydrocarbons having the above-mentioned characteristics may be employed singu
  • it will be larly or in compatible admixtures.
  • other non-toxic propellants having a vapor pressure without the limits prescribed above may be utilized in compatible admixtures with or Without one or more propellants having the required vapor pressure providing that the vapor pressure of such mixtures is within the prescribed range.
  • The. presence of ethanol as a constituent of the liquid carrier is critically essential for the preparation of satisfactory self-propelling medicated compositions contemplated by the present invention.
  • the ethanol while also serving as additional diluent for the suspended medicated particles, is absolutely essential to prevent agglomeration or settling out of the medicated particles.
  • the discovery that ethanol can be utilized for the prevention of agglomeration or settling out of the medicated particles permits the preparation of stable self-propelling medicated compositions without the necessity of employing other agents, such as surfactants, for this purpose.
  • the medicaments employed in the compositions of this invention should, of course, -be therapeutically suitable for inhalation or ophthalmic therapy as the case may be.
  • the medicament be a solid at ordinary room temperature, substantially anhydrous in form and virtually insoluble in' the liquid carrier employed.
  • the medicament have a particle size of at least about 0.5 to- 1 micron and no greater than about microns.
  • the particle size of the-medicament is such that 95%- by' weight of the particles are in the range of from about 0.5 to about 4 microns.
  • the anti-inflammatory steroids such as hydro
  • medicaments may be employed in their free form or suitable derivatives such as estes, salts and the like may be utilized. It will, of course, be appreciated by those in the art that the selection of the particular form of the medicament employed will be dependent upon itssolubility characteristics in the particular carrier system utilized. In addition, it is preferred, but not essential, that the medicament utilized in the preparations intended for inhalation therapy also be water-soluble and for this purpose the form of medicament can be selected accordingly.
  • the amount of ethanol employed in the compositions of the present invention be kept at a minimum. Preferably, it should not exceed 5% by Weight of the final formulation because higher levels of ethanol may adversely affect the dispersion in that it may cause some reflocculation of the dispersed solids.
  • the ethanol is present in an amount of from about 0.5 to about 5.0% and preferably 1.5 to 3.0% by weight of the formulation. In those compositions intended for ophthalmic use, the amount of ethanol preferably should not exceed 3.0%.
  • the concentration of medicament in the self-propelled compositions of the present invention will, of course, vary depending on the medicament and carrier employed as Well as the treatment desired. However, in general, the amount of medicament should generally constitute from about 0.02% to about 5% and preferably from about 0.05% to about 1% by weight of the composition, with the propellant constituting the remainder of the composition.
  • the medicament is first ground, milled or micronized to a particle size in the range specified hereina-bove and then dried by conventional methods to substantially remove any water which may be present.
  • a desired amount of finely divided and substantially anhydrous medicament is then suspended in a measured amount of carrier which has previously been cooled to a temperature of about 25 F. ina suitable container.
  • the container which may be metal, glass or plastic is sealed with a closure equipped with a suitable dispensing valve arrangement.
  • the quantities of the components introduced into the container are calculated to provide the desired concentration in the final composition.
  • An alternative and preferred procedure for preparing the compositions of the invention comprises milling a suitable quantity of medicament, which has previously been dried to remove substantially all water, in ethanol, to form a suspension concentrate containing the medicament having the required particle size; subdividing and diluting the thus obtained concentrate in a suitable container with sufiicient propellant, previously cooled to about 25 F., to provide the desired concentration of the medicament and ethanol in the final formulation and, Without allowing the temperature of the formulation to rise above the boiling point of the propellant, sealing the container with a closure equipped with a suitable dispensing valve arrangement which is preferably metered to dispense an effective dose of the medicament per application or over several applications during a single day.
  • a suitable metered dispensing valve for this purpose is described in United States Patent No. [2,721,010.
  • the medicament considered for use in such preparations can be sterilized using ethylene oxide treatment in the conventional manner.
  • the propellant While not particularly susceptible to bacterial invasion, may, nevertheless, be sterilized by filtration.
  • the containers previously sterilized by usual procedures, are filled in a sterile area. Once filling is complete, sterility need not be a factor since the pressurized container is never opened.
  • Example 1 A self-propelling medicament composition suitable for inhalation therapy and containing the following ingredients is prepared as follows:
  • Percent by weight 13.5 grams of substantially dry dexamethasone phosphate and 5.35 grams of substantially dry isoproterenol sulfate are milled in 75 grams of absolute ethanol to a particle size in the range of from about 0.5 to microns.
  • the resulting suspension concentrate is then subdivided into 500 portions in suitable aerosol containers and each diluted with 14.81 grams of a propellant mixture, previously cooled to about 25 F., containing 35% Freon 12 and 65% Freon 114. Without permitting the temperature of the resulting formulations (which contain grams of material) to rise above the boiling point of the propellant component, the metal containers are then sealed with a closure equipped with a metered valve capable of dispensing the desired amount of medicament per application.
  • Example 2 A self-propelled medicament composition suitable for inhalation therapy and containing the following ingredients is prepared as follows:
  • Example 3v A self-propelled medicament composition suitable for inhalation therapy and containing the following ingredients is prepared as follows:
  • the medicaments previously dried to remove substantially all water, are milled in ethanol to a particle size in the range of about 0.5 to 10 microns.
  • Example 4 A self-propelled medicament composition suitable for ophthalmic therapy and containing the following ingredients is prepared as follows:
  • the medicament previously dried and sterilized, is milled in absolute ethanol to a particle size in the range of about 0.5 to 10 microns and the resulting suspension concentrate diluted with the sterile propellant component in a suitable container and the container sealed as described in Example 2.
  • Example! 5 A self-propelled medicament composition suitable for ophthalmic therapy and containing the following ingredients is prepared in accordance with the procedure of Example 4:
  • Example 6 A self-propelled medicament composition suitable for inhalation therapy and containing the following ingredients is prepared in accordance with the procedure of Example 2:
  • Example 7 A self-propelled medicament composition suitable for.
  • a self-propelled medicament composition suitable for inhalation therapy and containing the following ingredients is prepared in accordance with the procedure of Example 2:
  • the crystalline Zinc insulin previously dried to remove substantially all water, is milled in ethanol to a particle size range approximating 2 microns.
  • To the resulting suspension concentrate in a suitable container is then added the propellants, previously cooled to about 25 F. The remainder of the procedure is the same as in Example 2.
  • Using a 70 mg. metered valve there will be provided approximately 2 units of crystalline zinc insulin per increment of metered spray.
  • a regimen of ten sprays per day is suitable for the systemic treatment of diabetes and other diseases which respond to insulin therapy.
  • Example 10 Weight, g. Neomycin sulfate 1.0 Polyrnixin sulfate 1.0 Ethanol (absolute) 0.7
  • each increment of metered spray will provide approximately 5 mg. of each of the antibiotics for inhalation.
  • a regimen of three applications four times a day is suitable for the treatment of chronic bronchitis, allergic bronchitis and similar disorders.
  • a self-propelling medicament composition consisting essentially of a suspension of a solid, substantially anhydrous medicament in a substantially anhydrous liquid carrier comprised essentially of a mixture of a nontoxic propellant and ethanol, said medicament being substantially insoluble in said mixture of propellant and ethanol and having a particle size in the range of from about 0.5 to about microns, and said ethanol being present in an amount of from about 0.5% to not more than about 5% by weight of said composition, in order to thereby avoid some reflocculation of the dispersed solids caused by higher levels of ethanol.
  • composition of claim 1 wherein the particle size of the medicament is such that by weight of the particles are inthe range of from about 0.5 to about 4 microns.
  • composition of claim 3 wherein the medicament is isoproterenol sulfate
  • composition of claim 3 wherein the medicament is a mixture of dexamethasone and isoproterenol.
  • a package comprising a pressure-tight container having a valve-controlled opening and containing a selfpropelling medicament composition capable of providing a medicament in aerosol form consisting essentially of a suspension of a solid, substantially anhydrous medicament in a substantially anhydrous liquid carrier comprised substantially of a mixture of a non-toxic propellant and ethanol, said medicament being substantially insoluble in said mixture of propellant and ethanol and having a particle size in the range of from about 0.5 to about 10 microns, and said ethanol being present in an amount of from about 0.5% to not more than about 5% by weight of said composition, in order to thereby avoid some refiocculation of the dispersed solids caused by higher levels of ethanol.
  • a method for avoiding some refiocculation of dispersed solids caused by higher levels of ethanol in preparing self-propelled medicament compositions which comprises the steps of drying a solid medicament to remove substantially all water therefrom, reducing said substantially dry medicament to a particle size in the range of from about 0.5 to about 10 microns and suspending said medicament in a substantially anhydrous liquid carrier comprised essentially of a non-toxic propellant and an amount of ethanol suffi-cient to provide from about 0.5% to not more than about 5% by weight of said composition, thereby forming a suspension wherein said medicament is substantially insoluble in said mixture of propellant and ethanol.

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Otolaryngology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pulmonology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Description

United States Patent AEROSOL SOLID MEDICAMENT IN PROPELLANT AND LOW-LEVEL ETHANOL AVOIDING HIGH- ER-LEVEL ETHANOL DISPERSED-SOLID RE- FLOCCULATIGN John D. Mullins, Evansville, Ind., assignor to Mierck & Co., Inc., Railway, N.J., a corporation of New Jersey No Drawing. Filed N 0v. 29, 1962, Ser. No. 241,022
8 Claims. (Cl. 167-82) This invention relates to pharmaceutical compositions and more particularly to self-propelling medicament compositions and the method of treatment therewith. This application is a continuation-in-part of my application Serial No. 147,444, filed October 25, 1961, which in turn is a continuation-in-part of Serial No. 112,799, filed May 26, 1961, both now abandoned.
The administration of medicaments by inhalation has been known and employed with varying degrees of success for many years. Usually aqueous solutions of the medi cament were atomized by mechanical means and inhaled. Inhalation of medicated steam vapors has been employed. Insufilation of fine powders, again with the aid of mechanical devices, also has been practiced. However, in general, those devices which were eiiective in reducing the particles of medicament to a size compatible with entry into the bronchial tree were large, cumbersome and could not be employed outside of the home, clinic or hospital. Many of the smaller, portable devices were inefiicient or totally ineffective.
The introduction of nebulizers with rubber airbulbs to aspirate the medicament in the lung cavity represented a notable advance in more or less portable devices but their utility was limited because of great variations in pressure obtained depending upon how the device was used. A still further advance was the development of self-propelling medicament compositions such as described in United States Patent No. 2,868,691. Unfortunately, the compositions described therein are not as satisfactory as is desired for inhalation therapy because such compositions do not provide sufiicient deposition and retention of the medicated particles where needed to obtain maximum therapeutic eilect, namely, on the mucous memberanes of the bronchial tree.
As a result of the aforementioned problems, therapy by inhalation has gone through various cycles of use and disuse and today is not widely practiced. Yet in many conditions, particularly those which involve the respiratory tree, as in asthma, bronchitis, infectious and inflammatory diseases of the respiratory tract, and even coughing and the allergic manifestations of the common cold, proper inhalation therapy woud be exceedingly useful.
According to the present invention, there are now provided stable self-propelling medicated compositions which have the properties and characteristics which render them highly useful for both inhalation and ophthalmic therapy. The self-propelling compositions of this invention are substantially anhydrous suspensions or dispersions comprised essentially of a solid medicament uniformly dispersed or suspended throughout a substantially anhydrous liquid carrier comprised essentially of a non-toxic propellant and ethanol. These compositions, when prepared cmploying the above components, described more fully hereinafter, provide an excellent means for administering medicaments in aerosol form for inhalation and ophthalmic therapy. For example, it has been found that when the compositions of this invention are utilized for inhalation therapy there is obtained greater deposition and retention of the medicated particles in that region of the bronchial tree where it is optimally utilized. As a result of such efficient aerosolization of the medication upon target lung tissue, it is possible in many cases to significantly reduce the dose of the medication employed whereby, with some drugs, such as the anti-inflammatory steroids, 8. direct benefit accrues to the patient in the elimination of some of the classic side eilects of the drug encountered when they are administered over a prolonged period of time by mouth or by parenteral injection.
In addition to the above, it has also been found that by virtue of the etficient aerosolization of the medicament upon the lung tissue, the absorption of many medicaments into the blood stream is greatly enhanced. Accordingly, the compositions of the present invention are also particularly useful for the systemic treatment of various diseases of the body which have heretofore been treated by parenteral administration of antibiotics and other medicaments such as insulin, adrenaline and triodothyronine. Thus, for example, employing insulin as the medicament, diabetes and other diseases which respond to insulin therapy, may be treated by inhalation therapy utilizing the compositions of this invention. The treatment of such diseases by inhalation therapy obviates the need for administering the medicament via the parenteral route which is often discomforting to the patient. Furthermore, the treatment of such diseases by inhalation therapy utilizing the compositions of this invention minimizes or eliminates certain of the classic side effects associated with parenteral administration, particularly intravenous injection.
The self-propelled compositions of the present invention are also particularly useful for ophthalmic therapy. At present, medicaments are normally applied to the eye either in the form of aqueous suspensions or solutions or as ointments. In the former, the medicament is applied by dropper or eye cup whereas with the latter, application is made by pressing a small amount of ointment from a tube around the area of the eyelid which is then mechanically spread by movement of the eye itself. Both methods, however, present considerable problems, especially for self-medication. Thus, for example, accurate positioning is diflicult and the application is often wasteful and unsightly. Furthemore, utilizing these methods and compositions, the drug is administered to the eye by direct impact which may give rise to irritation. The self-propelling medicament compositions of this invention, on the other hand, can be self-applied more readily with appreciably less waste of the drug and without leaving any unsightly appearance as is the case with ophthalmic ointments. In addition, the self-propelled compositions of the present invention provide for the administration of the drug to the eye as a fine mist, thereby substantially eliminating the irritation and waste often resulting when the drug is administered by conventional means.
The liquid carrier employed in the novel compositions of this invention is com-prised essentially of a mixture of a non-toxic liquid propellant and ethanol. The propellant, which constitutes the major portion of the carrier, should be non-toxic, have a vapor pressure between about 15 and pounds, and preferably between about 35 and 40 pounds per square inch gauge at 70 F., and be completely miscible with ethanol. Among the propellants having the above characteristics are the fluorinated or fluorochlorinated lower saturated aliphatic hydrocarbons. The preferred propellants of this type are the halogenated alkanes containing not more than two carbon atoms and at least one fluorine atoms. Illustrative of these are trichloromonofluoromethane, dichlorodifluoromethane, monochlorotrifluoromethane, dichloromonofluoromethane and 1,2-dichloro-1,1,2,2-tetrafiuoroethane. These compounds are available commercially from E. I. du Pont de Nemours and Company under the trade name Freon.
It will be realized that the fluorinated or fluorochlorinated lower saturatedaliphatic hydrocarbons having the above-mentioned characteristics may be employed singu In addition, it will be larly or in compatible admixtures. further realized that other non-toxic propellants having a vapor pressure without the limits prescribed above may be utilized in compatible admixtures with or Without one or more propellants having the required vapor pressure providing that the vapor pressure of such mixtures is within the prescribed range.
The. presence of ethanol as a constituent of the liquid carrier is critically essential for the preparation of satisfactory self-propelling medicated compositions contemplated by the present invention. The ethanol, while also serving as additional diluent for the suspended medicated particles, is absolutely essential to prevent agglomeration or settling out of the medicated particles. The discovery that ethanol can be utilized for the prevention of agglomeration or settling out of the medicated particles permits the preparation of stable self-propelling medicated compositions without the necessity of employing other agents, such as surfactants, for this purpose. This represents a decided advancement of the art since it is now possible, for the first time, to prepare stable self-propelling compositions which upon ejection and inhalation thereof permits essentially only the medicament to enter the bronchial tree. This stems from the fact that during the ejectioninhalation cycle, the propellant and ethanol are so rapidly volatilized that very little, if any, enters the bronchial tree. This represents a decided advantage over inhalation compositions containing other agents to prevent agglomeration which, because of their physical properties necessarily reach the desired site of deposition together with the medicament.
The medicaments employed in the compositions of this invention should, of course, -be therapeutically suitable for inhalation or ophthalmic therapy as the case may be. In addition, it is critical in order to formulate the compositions of the present invention, that the medicament be a solid at ordinary room temperature, substantially anhydrous in form and virtually insoluble in' the liquid carrier employed. Furthermore, it is also critical that the medicament have a particle size of at least about 0.5 to- 1 micron and no greater than about microns. Pref erably, the particle size of the-medicament is such that 95%- by' weight of the particles are in the range of from about 0.5 to about 4 microns. With these critical requirements in mind, medicaments which can be satisfactorily employed in the self-propelled inhalation and/or ophthalmic compositions of this invention include insulin, triodo'thyronine and adrenaline; the anti-inflammatory steroids such as hydrocortisone, prednisolone and dexamethasone; antibiotics such as penicillin, neomycin, polymixin, tetracycline, chlortetracycline and oxytetracycline; broncho-dilators such as isoproterenol, phenisonone, epinephrine, phenylephri-ne and metaraminol; anti-nauseants such as cyclizine, meclizine, pipamazine, dimenhydrinate, trimethobenzamide; analgesics such as ergotamine; antihistamines such as cyproheptadine; antitussives such as noscapine, and mixtures thereof. These medicaments may be employed in their free form or suitable derivatives such as estes, salts and the like may be utilized. It will, of course, be appreciated by those in the art that the selection of the particular form of the medicament employed will be dependent upon itssolubility characteristics in the particular carrier system utilized. In addition, it is preferred, but not essential, that the medicament utilized in the preparations intended for inhalation therapy also be water-soluble and for this purpose the form of medicament can be selected accordingly.
It is important that the amount of ethanol employed in the compositions of the present invention be kept at a minimum. Preferably, it should not exceed 5% by Weight of the final formulation because higher levels of ethanol may adversely affect the dispersion in that it may cause some reflocculation of the dispersed solids. Desirably, the ethanol is present in an amount of from about 0.5 to about 5.0% and preferably 1.5 to 3.0% by weight of the formulation. In those compositions intended for ophthalmic use, the amount of ethanol preferably should not exceed 3.0%. The concentration of medicament in the self-propelled compositions of the present invention will, of course, vary depending on the medicament and carrier employed as Well as the treatment desired. However, in general, the amount of medicament should generally constitute from about 0.02% to about 5% and preferably from about 0.05% to about 1% by weight of the composition, with the propellant constituting the remainder of the composition.
In preparing the compositions of this invention, the medicament is first ground, milled or micronized to a particle size in the range specified hereina-bove and then dried by conventional methods to substantially remove any water which may be present. A desired amount of finely divided and substantially anhydrous medicament is then suspended in a measured amount of carrier which has previously been cooled to a temperature of about 25 F. ina suitable container. Without permitting the temperature of the suspension to rise above the boiling point of the propellant, the container which may be metal, glass or plastic is sealed with a closure equipped with a suitable dispensing valve arrangement. The quantities of the components introduced into the container are calculated to provide the desired concentration in the final composition. Upon Warming to room temperature, the contents of the container are mixed by agitation of the container.
An alternative and preferred procedure for preparing the compositions of the invention comprises milling a suitable quantity of medicament, which has previously been dried to remove substantially all water, in ethanol, to form a suspension concentrate containing the medicament having the required particle size; subdividing and diluting the thus obtained concentrate in a suitable container with sufiicient propellant, previously cooled to about 25 F., to provide the desired concentration of the medicament and ethanol in the final formulation and, Without allowing the temperature of the formulation to rise above the boiling point of the propellant, sealing the container with a closure equipped with a suitable dispensing valve arrangement which is preferably metered to dispense an effective dose of the medicament per application or over several applications during a single day. A suitable metered dispensing valve for this purpose is described in United States Patent No. [2,721,010.
Since, in all ophthalmic formulations, sterility must be assured, this factor must be considered. The medicament considered for use in such preparations can be sterilized using ethylene oxide treatment in the conventional manner. The propellant, While not particularly susceptible to bacterial invasion, may, nevertheless, be sterilized by filtration. The containers, previously sterilized by usual procedures, are filled in a sterile area. Once filling is complete, sterility need not be a factor since the pressurized container is never opened.
The following examples illustrate the preparation of specific compositions provided by this invention but it is understood that the invention is not to be restricted thereby to the embodiments described in these examples.
,5. Example 1 A self-propelling medicament composition suitable for inhalation therapy and containing the following ingredients is prepared as follows:
Percent by weight 13.5 grams of substantially dry dexamethasone phosphate and 5.35 grams of substantially dry isoproterenol sulfate are milled in 75 grams of absolute ethanol to a particle size in the range of from about 0.5 to microns. The resulting suspension concentrate is then subdivided into 500 portions in suitable aerosol containers and each diluted with 14.81 grams of a propellant mixture, previously cooled to about 25 F., containing 35% Freon 12 and 65% Freon 114. Without permitting the temperature of the resulting formulations (which contain grams of material) to rise above the boiling point of the propellant component, the metal containers are then sealed with a closure equipped with a metered valve capable of dispensing the desired amount of medicament per application. Using a metered 70 mg. valve, there will be provided 0.126 mg. of the steroid and 0.049 mg. of the isoproterenol sulfate per application. A regimen of 3 applications four times a day of the formulation is suitable for inhalation therapy.
Example 2 A self-propelled medicament composition suitable for inhalation therapy and containing the following ingredients is prepared as follows:
Weight, g.
Dexamethasone phosphate, disodium 0.027
Ethanol (absolute) 0.150
Dichlorodifiuoromethane (Freon 12) 5.188 1,2-dichloro-1, 1,2,2-tetrafluoroethane (Freon 114) 9.635
Example 3v A self-propelled medicament composition suitable for inhalation therapy and containing the following ingredients is prepared as follows:
Weight, g. Dexamethasone phosphate, disodium 0.027 Isoproterenol sulfate 0.011 Ethanol (absolute) 0.300 Dichlorodifiuoromethane (Freon 12) 5.132 1,2-dichloro-l,1,2,2-tetrafluoroethane (Freon 114) 9.530
The medicaments, previously dried to remove substantially all water, are milled in ethanol to a particle size in the range of about 0.5 to 10 microns. To the resulting suspension concentrate in a suitable container is then added the propellants, previously cooled to about 25 F. The remainder of the procedure is the same as in Example 2.
Example 4 A self-propelled medicament composition suitable for ophthalmic therapy and containing the following ingredients is prepared as follows:
Weight, g.
Dexamethasone phosphate, disodium 0.027
Ethanol (absolute) 0.300
Dichlorodifluoromethane (Freon 12) 5.136 1,2-dichloro-1,1,2,2-tetrafluoroethane (Freon 114) 9.537
The medicament, previously dried and sterilized, is milled in absolute ethanol to a particle size in the range of about 0.5 to 10 microns and the resulting suspension concentrate diluted with the sterile propellant component in a suitable container and the container sealed as described in Example 2.
Example! 5 A self-propelled medicament composition suitable for ophthalmic therapy and containing the following ingredients is prepared in accordance with the procedure of Example 4:
Weight, g. Prednisolone alcohol 0.050 Ethanol (absolute) 0.150 Dichlorodifluoromethane (Freon 12) 5.18
1,2-dichloro-1,l, 2,2-tetrafiuoroethane (Freon 1'1 4)- 9.62
Example 6 A self-propelled medicament composition suitable for inhalation therapy and containing the following ingredients is prepared in accordance with the procedure of Example 2:
Weight, g. Epinephrine hydrochloride 0.025 Ethanol (absolute) 0.150 Dichlorodifluoromethane (Freon 12) 5.189
1,2-dich1oro-1,1,2,2-tetrafiuoroethane (Freon 114) 9.636
Example 7 A self-propelled medicament composition suitable for.
both inhalation and ophthalmic therapy and containing the following ingredients is prepared in accordance with the procedure of Example 3, except that the medicament, propellant and container are all sterilized prior to use:
A self-propelled medicament composition suitable for inhalation therapy and containing the following ingredients is prepared in accordance with the procedure of Example 2:
Weight, g. Dexamethasone phosphate, disodium 0.027 Isoproterenol sulfate 0.011 Ethanol (absolute) 0.450 Dichliorodifiuoromethane(Freon 1 2) 5.079
1,2 dichloro 1,i1,2,2 tetrafluoroethane (Freon Example 9 A self-propelling medicament composition suitable for inhalation therapy and containing the following ingredients is prepared as follows:
Weight Crystalline zinc insulin 400 units (18.2 mg). Ethanol (absolute) 0.280 g. Dichlorodifluoromethane (Freonl-Z) 4.796 g. 1,2 dichloro 1,1,2,2-tetrafluoroethane (Freon 114) 8.906 g.
The crystalline Zinc insulin, previously dried to remove substantially all water, is milled in ethanol to a particle size range approximating 2 microns. To the resulting suspension concentrate in a suitable container is then added the propellants, previously cooled to about 25 F. The remainder of the procedure is the same as in Example 2. Using a 70 mg. metered valve, there will be provided approximately 2 units of crystalline zinc insulin per increment of metered spray. A regimen of ten sprays per day is suitable for the systemic treatment of diabetes and other diseases which respond to insulin therapy.
Example 10 Weight, g. Neomycin sulfate 1.0 Polyrnixin sulfate 1.0 Ethanol (absolute) 0.7
Dichl-orodifluoromethane (Freon 12) 3.9 1,2-dichloro 1,1,2,2-tetrafluoroethane (Freon l-14) 7.35
Using a 70 mg. metered valve, each increment of metered spray will provide approximately 5 mg. of each of the antibiotics for inhalation. A regimen of three applications four times a day is suitable for the treatment of chronic bronchitis, allergic bronchitis and similar disorders.
While the foregoing specification has beenv set forth by way of illustration, it will be understood that various modifications and changes may be made without departing from the spirit and scope of the present invention which is to be limited only by the scope of the appended claims.
I claim:
1. A self-propelling medicament composition consisting essentially of a suspension of a solid, substantially anhydrous medicament in a substantially anhydrous liquid carrier comprised essentially of a mixture of a nontoxic propellant and ethanol, said medicament being substantially insoluble in said mixture of propellant and ethanol and having a particle size in the range of from about 0.5 to about microns, and said ethanol being present in an amount of from about 0.5% to not more than about 5% by weight of said composition, in order to thereby avoid some reflocculation of the dispersed solids caused by higher levels of ethanol.
2. The composition of claim 1 wherein the particle size of the medicament is such that by weight of the particles are inthe range of from about 0.5 to about 4 microns.
3. The composition of claim 2 wherein the ethanol is present inan amount of from about 1 /2 to 3% by weight of saidcomposition.
4. The-composition-of claim3- wherein the medicament is dexamethasone-disodium phosphate.
5. The composition of claim 3 wherein the medicament is isoproterenol sulfate;
6. The composition of claim 3 wherein the medicament is a mixture of dexamethasone and isoproterenol.
7. A package comprising a pressure-tight container having a valve-controlled opening and containing a selfpropelling medicament composition capable of providing a medicament in aerosol form consisting essentially of a suspension of a solid, substantially anhydrous medicament in a substantially anhydrous liquid carrier comprised esentially of a mixture of a non-toxic propellant and ethanol, said medicament being substantially insoluble in said mixture of propellant and ethanol and having a particle size in the range of from about 0.5 to about 10 microns, and said ethanol being present in an amount of from about 0.5% to not more than about 5% by weight of said composition, in order to thereby avoid some refiocculation of the dispersed solids caused by higher levels of ethanol.
8. A method for avoiding some refiocculation of dispersed solids caused by higher levels of ethanol in preparing self-propelled medicament compositions which comprises the steps of drying a solid medicament to remove substantially all water therefrom, reducing said substantially dry medicament to a particle size in the range of from about 0.5 to about 10 microns and suspending said medicament in a substantially anhydrous liquid carrier comprised essentially of a non-toxic propellant and an amount of ethanol suffi-cient to provide from about 0.5% to not more than about 5% by weight of said composition, thereby forming a suspension wherein said medicament is substantially insoluble in said mixture of propellant and ethanol.
References Cited by the Examiner OTHER REFERENCES Abramson: The Role of Particle Size in Inhalation Therapy by Atomization and by Penicillin Dusts, Diseases of the chest 18: 435-449, November 1950.
AMA Archives of Dermatology, vol. 79, No. 1, pp.
103-1 05, entries: Prednisolone in Aerosol Form, Reisset al.; Prednisolone (Meti-Derm) As an Aerosol for Dermatoses,Robinson, January 1959.
Duvenci et al.: Dexamethasone Therapy in Bronchial Asthma, Ann Allergy 17: 695-700, September- October 1959.
Falliers et al.: Dexamethasone in Childhood Asthma," Ann. Allergy 17: NovemberDecember 1959, pp. 887- 894.
(Other references on following page) 9 OTHER REFERENCES Franklin et 211.: Aerosolized Steroids in Bronchial Asthma, J. Allergy 29 (3): 214-221, May 1958.
Lovejoy et al.: Importance of Particle Size in Aerosol Therapy, Proc. Soc. Exp. Biol. Med. 103: 836838, April 1960.
Porush et al.: Pressurized Pharmaceutical Aerosols 10 for Inhalation Therapy, J. Am. Pharm. Assn. (Sci. Ed.), 49 (2): 70-74, February 1960.
Streseman: The Dosage of Dexamethasone and Triarncinolone in Bronchial Asthma, Lancet 2: 257-258, September 5, 1959.
LEWIS GOTTS, Primary Examiner.

Claims (1)

1. A SELF-PROPELLING MEDICAMENT COMPOSITION CONSISTING ESSENTIALLY OF A SUSPENSION OF A SOLID, SUBSTANTIALLY ANHYDROUS MEDICAMENT IN A SUBSTANTIALLY ANHYDROUS LIQUID CARRIER COMPRISED ESSENTIALLY OF A MIXTURE OF A NONTOXIC PROPELLANT AND ETHANOL, SAID MEDICAMENT BEING SUBSTANTIALLY INSOLUBLE IN SAID MIXTURE OF PROPELLANT AND ETHANOL AND HAVING A PARTICLE SIZE IN THE RANGE OF FROM ABOUT 0.5 TO ABOUT 10 MICRONS, AND SAID ETHANOL BEING PRESENT IN AN AMOUNT OF FROM ABOUT 0.5% TO NOT MORE THAN ABOUT 5% BY WEIGHT OF SAID COMPOSITION, IN ORDER TO THEREBY AVOID SOME REFLOCCULATION OF THE DISPERSED SOLIDS CAUSED BY HIGHER LEVEL OF ETHANOL.
US241022A 1962-11-29 1962-11-29 Aerosol solid medicament in propellant and low-level ethanol avoiding higher-level ethanol dispersed-solid reflocculation Expired - Lifetime US3219533A (en)

Priority Applications (6)

Application Number Priority Date Filing Date Title
BE629985D BE629985A (en) 1962-11-29
NL289785D NL289785A (en) 1962-11-29
US241022A US3219533A (en) 1962-11-29 1962-11-29 Aerosol solid medicament in propellant and low-level ethanol avoiding higher-level ethanol dispersed-solid reflocculation
GB8798/63A GB1018125A (en) 1962-11-29 1963-03-05 Chemical products
DE19631492015 DE1492015A1 (en) 1962-11-29 1963-03-15 Improved form of administration of pharmaceutical preparations
FR932382A FR1381252A (en) 1962-11-29 1963-04-23 Self-propelled medication vehicles

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US241022A US3219533A (en) 1962-11-29 1962-11-29 Aerosol solid medicament in propellant and low-level ethanol avoiding higher-level ethanol dispersed-solid reflocculation

Publications (1)

Publication Number Publication Date
US3219533A true US3219533A (en) 1965-11-23

Family

ID=22908922

Family Applications (1)

Application Number Title Priority Date Filing Date
US241022A Expired - Lifetime US3219533A (en) 1962-11-29 1962-11-29 Aerosol solid medicament in propellant and low-level ethanol avoiding higher-level ethanol dispersed-solid reflocculation

Country Status (5)

Country Link
US (1) US3219533A (en)
BE (1) BE629985A (en)
DE (1) DE1492015A1 (en)
GB (1) GB1018125A (en)
NL (1) NL289785A (en)

Cited By (146)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3282791A (en) * 1965-08-17 1966-11-01 Merck & Co Inc Inhalation aerosol suspension of anhydrous disodium dexamethasone phosphate, propellents, and sorbitan trioleate
US3482015A (en) * 1965-02-08 1969-12-02 Merck & Co Inc Aerosol composition of phenylephrine tartrate and the production of such
US3897779A (en) * 1973-06-27 1975-08-05 American Cyanamid Co Triamcinolone acetonide inhalation therapy
EP0091313A3 (en) * 1982-04-05 1985-05-22 Alcon Laboratories Inc Perfluorohydrocarbons as vehicles for administering drugs
US4581225A (en) * 1984-04-25 1986-04-08 Eli Lilly And Company Sustained release intranasal formulation and method of use thereof
US5439670A (en) * 1989-11-28 1995-08-08 Riker Laboratories, Inc. Medicinal aerosol formulations
US5603918A (en) * 1995-06-09 1997-02-18 Boehringer Ingelheim Pharmaceuticals, Inc. Aerosol composition of a salt of ipratropium and a salt of albuterol
US5605674A (en) * 1988-12-06 1997-02-25 Riker Laboratories, Inc. Medicinal aerosol formulations
US5653962A (en) * 1991-12-12 1997-08-05 Glaxo Group Limited Aerosol formulations containing P134a and particulate medicaments
US5658549A (en) * 1991-12-12 1997-08-19 Glaxo Group Limited Aerosol formulations containing propellant 134a and fluticasone propionate
US5674471A (en) * 1991-12-12 1997-10-07 Glaxo Group Limited Aerosol formulations containing P134a and salbutamol
US5674472A (en) * 1991-12-12 1997-10-07 Glaxo Group Limited Canisters containing aerosol formulations containing P134a and fluticasone propionate
US5736124A (en) * 1991-12-12 1998-04-07 Glaxo Group Limited Aerosol formulations containing P134a and particulate medicament
US5744123A (en) * 1991-12-12 1998-04-28 Glaxo Group Limited Aerosol formulations containing P134a and particulate medicaments
US5766573A (en) * 1988-12-06 1998-06-16 Riker Laboratories, Inc. Medicinal aerosol formulations
US5785952A (en) * 1990-11-09 1998-07-28 Glaxo Group Limited Aerosol medicament formulation having a surface coating of surfactant
US5817293A (en) * 1991-12-12 1998-10-06 Glaxo Group Limited Canister containing aerosol formulations containing P134a and particulate medicaments
US5916540A (en) * 1994-10-24 1999-06-29 Glaxo Group Limited Aerosol formulations containing P134A and/or P227 and particulate medicament
US5919435A (en) * 1990-11-09 1999-07-06 Glaxo Group Limited Aerosol formulation containing a particulate medicament
US5922306A (en) * 1991-12-12 1999-07-13 Glaxo Group Limited Aerosol formulations containing P134a and particulate medicament
WO2002094245A1 (en) * 2001-05-24 2002-11-28 Alexza Molecular Delivery Corporation Delivery of antihistamines through an inhalation route
US20030032632A1 (en) * 1999-12-24 2003-02-13 Crispps Leslie Alan Pharmaceutical aerosol formulation of salmeterol and fluticasone propionate
WO2003015750A1 (en) * 2001-08-16 2003-02-27 Baxter International, Inc. Propellant-based microparticle formulations
US20030059474A1 (en) * 1999-10-18 2003-03-27 Scott Terrence L. Sustained release microspheres
US20030232876A1 (en) * 1996-08-16 2003-12-18 Pozen, Inc. Methods of treating headaches using 5-HT agonists in combination with long-acting NSAIDs
US6740308B2 (en) 2001-05-24 2004-05-25 Alexza Molecular Delivery Corporation Delivery of antihistamines through an inhalation route
US6743413B1 (en) 1991-12-18 2004-06-01 3M Company Suspension aerosol formulations
US20040127490A1 (en) * 2001-05-24 2004-07-01 Alexza Molecular Delivery Corporation Delivery of alprazolam, estazolam midazolam or triazolam through an inhalation route
US20040157815A1 (en) * 1999-09-11 2004-08-12 Smithkline Beecham Corporation Pharmaceutical formulation of fluticasone propionate
US20040171609A1 (en) * 2001-11-09 2004-09-02 Alexza Molecular Delivery Corporation Delivery of diazepam through an inhalation route
US20040170572A1 (en) * 2001-05-24 2004-09-02 Alexza Molecular Delivery Corporation Delivery of rizatriptan or zolmitriptan through an inhalation route
US20050031548A1 (en) * 1990-02-03 2005-02-10 Boehringer Ingelheim Kg Suspension aerosol formulations of pharmaceutical products
US20050048001A1 (en) * 1999-11-23 2005-03-03 Cripps Alan Leslie Pharmaceutical formulations of salmeterol
US7090830B2 (en) 2001-05-24 2006-08-15 Alexza Pharmaceuticals, Inc. Drug condensation aerosols and kits
US7101534B1 (en) 1991-12-18 2006-09-05 3M Innovative Properties Company Suspension aerosol formulations
US7105152B1 (en) 1991-12-18 2006-09-12 3M Innovative Properties Company Suspension aerosol formulations
US20070020299A1 (en) * 2003-12-31 2007-01-25 Pipkin James D Inhalant formulation containing sulfoalkyl ether cyclodextrin and corticosteroid
US20070020196A1 (en) * 2003-12-31 2007-01-25 Pipkin James D Inhalant formulation containing sulfoalkyl ether cyclodextrin and corticosteroid prepared from a unit dose suspension
US20070160542A1 (en) * 2005-12-20 2007-07-12 Verus Pharmaceuticals, Inc. Methods and systems for the delivery of corticosteroids having an enhanced pharmacokinetic profile
US20070178050A1 (en) * 2005-12-20 2007-08-02 Verus Pharmaceuticals, Inc. Methods and systems for the delivery of corticosteroids having an increased lung depositon
US20070178049A1 (en) * 2005-12-20 2007-08-02 Verus Pharmaceuticals, Inc. Systems and methods for the delivery of corticosteroids having an enhanced pharmacokinetic profile
US20070185066A1 (en) * 2005-12-20 2007-08-09 Verus Pharmaceuticals, Inc. Systems and methods for the delivery of corticosteroids
US20070197486A1 (en) * 2005-12-20 2007-08-23 Verus Pharmaceuticals, Inc. Methods and systems for the delivery of corticosteroids
US20070197487A1 (en) * 2005-12-20 2007-08-23 Verus Pharmaceuticals, Inc. Systems and methods for the delivery of corticosteroids having an increased lung deposition
US20070249572A1 (en) * 2005-12-20 2007-10-25 Verus Pharmaceuticals, Inc. Systems and methods for the delivery of corticosteroids
US20080076997A1 (en) * 1998-04-30 2008-03-27 Abbott Diabetes Care, Inc. Analyte monitoring device and methods of use
US20080107741A1 (en) * 2002-03-20 2008-05-08 Elan Pharma International Ltd. Nanoparticulate compositions of angiogenesis inhibitors
US7374782B2 (en) 2000-10-27 2008-05-20 Baxter International Inc. Production of microspheres
EP1944016A1 (en) 2001-08-16 2008-07-16 Baxter International Inc. Propellant-based microparticle formulatons
EP1718276A4 (en) * 2003-12-31 2008-07-23 Cydex Inc Inhalant formulation containing sulfoalkylether cyclodextrin and corticosteroid prepared from a unit dose suspension
US20080287451A1 (en) * 2007-02-11 2008-11-20 Cook Robert O Method of therapeutic administration of DHE to enable rapid relief of migraine while minimizing side effect profile
US7458374B2 (en) 2002-05-13 2008-12-02 Alexza Pharmaceuticals, Inc. Method and apparatus for vaporizing a compound
US7498019B2 (en) 2001-05-24 2009-03-03 Alexza Pharmaceuticals, Inc. Delivery of compounds for the treatment of headache through an inhalation route
US7519408B2 (en) 2003-11-19 2009-04-14 Dexcom, Inc. Integrated receiver for continuous analyte sensor
US7537009B2 (en) 2001-06-05 2009-05-26 Alexza Pharmaceuticals, Inc. Method of forming an aerosol for inhalation delivery
US7540286B2 (en) 2004-06-03 2009-06-02 Alexza Pharmaceuticals, Inc. Multiple dose condensation aerosol devices and methods of forming condensation aerosols
US20090142407A1 (en) * 2000-09-01 2009-06-04 Meda Pharama Gmbh & Co. Kg Solid peptide preparations for inhalation and their preparation
US20090140851A1 (en) * 2007-12-04 2009-06-04 Nortel Networks Limited Systems and methods for facilitating a first response mission at an incident scene using patient monitoring
US7550133B2 (en) 2002-11-26 2009-06-23 Alexza Pharmaceuticals, Inc. Respiratory drug condensation aerosols and methods of making and using them
US20090181100A1 (en) * 1998-11-12 2009-07-16 Elan Pharma International Ltd Dry powder aerosols of Nanoparticulate drugs
US20090191134A1 (en) * 2006-06-12 2009-07-30 Medispray Laboratoriespvt. Ltd. Stable aerosol pharmaceutical formulations
US7581540B2 (en) 2004-08-12 2009-09-01 Alexza Pharmaceuticals, Inc. Aerosol drug delivery device incorporating percussively activated heat packages
US7582284B2 (en) 2002-04-17 2009-09-01 Nektar Therapeutics Particulate materials
US7583990B2 (en) 2003-08-01 2009-09-01 Dexcom, Inc. System and methods for processing analyte sensor data
US7585493B2 (en) 2001-05-24 2009-09-08 Alexza Pharmaceuticals, Inc. Thin-film drug delivery article and method of use
US7591801B2 (en) * 2004-02-26 2009-09-22 Dexcom, Inc. Integrated delivery device for continuous glucose sensor
US7640048B2 (en) 2004-07-13 2009-12-29 Dexcom, Inc. Analyte sensor
US7637868B2 (en) 2004-01-12 2009-12-29 Dexcom, Inc. Composite material for implantable device
US7645442B2 (en) 2001-05-24 2010-01-12 Alexza Pharmaceuticals, Inc. Rapid-heating drug delivery article and method of use
US7657297B2 (en) 2004-05-03 2010-02-02 Dexcom, Inc. Implantable analyte sensor
EP1406592A4 (en) * 2001-07-18 2010-03-17 Aeropharm Technology Inc A salt/ion pair medicinal aerosol formulation
US7715893B2 (en) 2003-12-05 2010-05-11 Dexcom, Inc. Calibration techniques for a continuous analyte sensor
US20100179407A1 (en) * 2003-08-22 2010-07-15 Dexcom, Inc. Systems and methods for replacing signal artifacts in a glucose sensor data stream
US7771352B2 (en) 1997-03-04 2010-08-10 Dexcom, Inc. Low oxygen in vivo analyte sensor
US7783333B2 (en) 2004-07-13 2010-08-24 Dexcom, Inc. Transcutaneous medical device with variable stiffness
US20100312078A1 (en) * 1998-04-30 2010-12-09 Abbott Diabetes Care Inc. Analyte Monitoring Device and Methods of Use
US7885697B2 (en) 2004-07-13 2011-02-08 Dexcom, Inc. Transcutaneous analyte sensor
US7896809B2 (en) 2003-07-25 2011-03-01 Dexcom, Inc. Dual electrode system for a continuous analyte sensor
US7905833B2 (en) 2004-07-13 2011-03-15 Dexcom, Inc. Transcutaneous analyte sensor
US7913688B2 (en) 2002-11-27 2011-03-29 Alexza Pharmaceuticals, Inc. Inhalation device for producing a drug aerosol
US7914450B2 (en) 2003-08-01 2011-03-29 Dexcom, Inc. System and methods for processing analyte sensor data
US7920906B2 (en) 2005-03-10 2011-04-05 Dexcom, Inc. System and methods for processing analyte sensor data for sensor calibration
US7920907B2 (en) 2006-06-07 2011-04-05 Abbott Diabetes Care Inc. Analyte monitoring system and method
US7976778B2 (en) 2001-04-02 2011-07-12 Abbott Diabetes Care Inc. Blood glucose tracking apparatus
US7981401B2 (en) 2002-11-26 2011-07-19 Alexza Pharmaceuticals, Inc. Diuretic aerosols and methods of making and using them
US8000901B2 (en) 2003-08-01 2011-08-16 Dexcom, Inc. Transcutaneous analyte sensor
US8005524B2 (en) 2003-12-09 2011-08-23 Dexcom, Inc. Signal processing for continuous analyte sensor
US8003080B2 (en) 2002-05-13 2011-08-23 Alexza Pharmaceuticals, Inc. Delivery of drug amines through an inhalation route
US8080236B2 (en) 2002-04-17 2011-12-20 Nektar Therapeutics Uk, Ltd Particulate materials
US8160669B2 (en) 2003-08-01 2012-04-17 Dexcom, Inc. Transcutaneous analyte sensor
US20120111324A1 (en) * 2007-10-22 2012-05-10 Board Of Regents, The University Of Texas System Dry Powder Drug Delivery Formulations, Methods of Use, and Devices Therefore
US8229535B2 (en) 2008-02-21 2012-07-24 Dexcom, Inc. Systems and methods for blood glucose monitoring and alert delivery
US8233959B2 (en) 2003-08-22 2012-07-31 Dexcom, Inc. Systems and methods for processing analyte sensor data
US8235037B2 (en) 2001-05-24 2012-08-07 Alexza Pharmaceuticals, Inc. Drug condensation aerosols and kits
US8260393B2 (en) 2003-07-25 2012-09-04 Dexcom, Inc. Systems and methods for replacing signal data artifacts in a glucose sensor data stream
US8275437B2 (en) 2003-08-01 2012-09-25 Dexcom, Inc. Transcutaneous analyte sensor
US8280475B2 (en) 2004-07-13 2012-10-02 Dexcom, Inc. Transcutaneous analyte sensor
US8287454B2 (en) 1998-04-30 2012-10-16 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
US8287453B2 (en) 2003-12-05 2012-10-16 Dexcom, Inc. Analyte sensor
US8290559B2 (en) 2007-12-17 2012-10-16 Dexcom, Inc. Systems and methods for processing sensor data
US8288372B2 (en) 2002-11-26 2012-10-16 Alexza Pharmaceuticals, Inc. Method for treating headache with loxapine
US8346337B2 (en) 1998-04-30 2013-01-01 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
US8367734B1 (en) 2005-08-11 2013-02-05 Amphastar Pharmaceuticals Inc. Stable epinephrine suspension formulation with high inhalation delivery efficiency
US8369919B2 (en) 2003-08-01 2013-02-05 Dexcom, Inc. Systems and methods for processing sensor data
US8387612B2 (en) 2003-05-21 2013-03-05 Alexza Pharmaceuticals, Inc. Self-contained heating unit and drug-supply unit employing same
US8396528B2 (en) 2008-03-25 2013-03-12 Dexcom, Inc. Analyte sensor
US8417312B2 (en) 2007-10-25 2013-04-09 Dexcom, Inc. Systems and methods for processing sensor data
US8423113B2 (en) 2003-07-25 2013-04-16 Dexcom, Inc. Systems and methods for processing sensor data
US8465425B2 (en) 1998-04-30 2013-06-18 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
US8548553B2 (en) 2003-08-01 2013-10-01 Dexcom, Inc. System and methods for processing analyte sensor data
US8560039B2 (en) 2008-09-19 2013-10-15 Dexcom, Inc. Particle-containing membrane and particulate electrode for analyte sensors
US8562558B2 (en) 2007-06-08 2013-10-22 Dexcom, Inc. Integrated medicament delivery device for use with continuous analyte sensor
US8565848B2 (en) 2004-07-13 2013-10-22 Dexcom, Inc. Transcutaneous analyte sensor
US8612159B2 (en) 1998-04-30 2013-12-17 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
US8622905B2 (en) 2003-08-01 2014-01-07 Dexcom, Inc. System and methods for processing analyte sensor data
US8652043B2 (en) 2001-01-02 2014-02-18 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
US8688188B2 (en) 1998-04-30 2014-04-01 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
US8777853B2 (en) 2003-08-22 2014-07-15 Dexcom, Inc. Systems and methods for replacing signal artifacts in a glucose sensor data stream
US8792955B2 (en) 2004-05-03 2014-07-29 Dexcom, Inc. Transcutaneous analyte sensor
US8808228B2 (en) 2004-02-26 2014-08-19 Dexcom, Inc. Integrated medicament delivery device for use with continuous analyte sensor
US8845536B2 (en) 2003-08-01 2014-09-30 Dexcom, Inc. Transcutaneous analyte sensor
US8886273B2 (en) 2003-08-01 2014-11-11 Dexcom, Inc. Analyte sensor
US8974386B2 (en) 1998-04-30 2015-03-10 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
US9066695B2 (en) 1998-04-30 2015-06-30 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
US9135402B2 (en) 2007-12-17 2015-09-15 Dexcom, Inc. Systems and methods for processing sensor data
US9155496B2 (en) 1997-03-04 2015-10-13 Dexcom, Inc. Low oxygen in vivo analyte sensor
US9282925B2 (en) 2002-02-12 2016-03-15 Dexcom, Inc. Systems and methods for replacing signal artifacts in a glucose sensor data stream
US9446194B2 (en) 2009-03-27 2016-09-20 Dexcom, Inc. Methods and systems for promoting glucose management
US9451908B2 (en) 2006-10-04 2016-09-27 Dexcom, Inc. Analyte sensor
US9451910B2 (en) 2007-09-13 2016-09-27 Dexcom, Inc. Transcutaneous analyte sensor
US9724028B2 (en) 2006-02-22 2017-08-08 Dexcom, Inc. Analyte sensor
US9757061B2 (en) 2006-01-17 2017-09-12 Dexcom, Inc. Low oxygen in vivo analyte sensor
US9986942B2 (en) 2004-07-13 2018-06-05 Dexcom, Inc. Analyte sensor
US10653835B2 (en) 2007-10-09 2020-05-19 Dexcom, Inc. Integrated insulin delivery system with continuous glucose sensor
US10813577B2 (en) 2005-06-21 2020-10-27 Dexcom, Inc. Analyte sensor
US10980461B2 (en) 2008-11-07 2021-04-20 Dexcom, Inc. Advanced analyte sensor calibration and error detection
US11000215B1 (en) 2003-12-05 2021-05-11 Dexcom, Inc. Analyte sensor
US11331022B2 (en) 2017-10-24 2022-05-17 Dexcom, Inc. Pre-connected analyte sensors
US11350862B2 (en) 2017-10-24 2022-06-07 Dexcom, Inc. Pre-connected analyte sensors
US11382539B2 (en) 2006-10-04 2022-07-12 Dexcom, Inc. Analyte sensor
US11399745B2 (en) 2006-10-04 2022-08-02 Dexcom, Inc. Dual electrode system for a continuous analyte sensor
US11559260B2 (en) 2003-08-22 2023-01-24 Dexcom, Inc. Systems and methods for processing analyte sensor data
US11633133B2 (en) 2003-12-05 2023-04-25 Dexcom, Inc. Dual electrode system for a continuous analyte sensor
US11642473B2 (en) 2007-03-09 2023-05-09 Alexza Pharmaceuticals, Inc. Heating unit for use in a drug delivery device
US12214118B2 (en) 2018-02-02 2025-02-04 Alexza Pharmaceuticals, Inc. Electrical condensation aerosol device
US12370352B2 (en) 2007-06-28 2025-07-29 Cydex Pharmaceuticals, Inc. Nasal and ophthalmic delivery of aqueous corticosteroid solutions

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI63672C (en) * 1980-05-19 1983-08-10 Orion Yhtymae Oy FOERFARANDE FOER FRAMSTAELLNING AV EN BLANDNING AV BEKLOMETASONDIPROPIONAT OCH TRIKLORFLUORMETAN ELLER DIKLORDIFLUORMETAN
JPS59163313A (en) * 1983-03-09 1984-09-14 Teijin Ltd Peptide hormone composition for nasal administration
FR2621817B1 (en) * 1987-10-19 1990-12-14 Medipro DRUG COMPRISING POLYMYXIN B, TOBRAMYCIN AND AMPHOTERICIN B VAPORIZED
FR2621818B1 (en) * 1987-10-19 1990-12-14 Medipro MEDICINE COMPRISING THE COMBINATION OF POLYMIXIN B, NETILMICIN AND AMPHOTERICIN B BY VAPORIZATION

Citations (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2782975A (en) * 1955-04-20 1957-02-26 American Cyanamid Co Sprayable amorphous antibiotic composition, pressurized container with same, and method of preparing
US2798836A (en) * 1954-01-18 1957-07-09 American Cyanamid Co Inhalable live virus veterinary vaccine
US2798835A (en) * 1954-01-18 1957-07-09 American Cyanamid Co Newcastle disease and infectious bronchitis vaccines and production thereof
US2801201A (en) * 1953-04-09 1957-07-30 Lincoln Lab Inc Burn treatment filling for pressure packaged dispenser
US2802772A (en) * 1954-09-09 1957-08-13 Merck & Co Inc Aerosols compositions; bomb, and process for treating flocks of chickens
US2959325A (en) * 1954-04-29 1960-11-08 Risdon Mfg Co Method and apparatus for dispensing dry powders
US2987439A (en) * 1958-01-07 1961-06-06 William Cooper & Nephews Inc Method of applying an aerosol to the eye
US3014844A (en) * 1957-01-31 1961-12-26 Riker Laboratories Inc Self-propelling powder dispensing compositions
US3028308A (en) * 1959-10-01 1962-04-03 Merck & Co Inc Dry pharmaceutical vehicle of copolymer of hydrolyzed gelatin and glyoxal, and its production
US3039929A (en) * 1960-03-17 1962-06-19 Abbott Lab Stable isoproteronol compositions
US3073743A (en) * 1959-07-30 1963-01-15 Upjohn Co Antiinflammatory steroid acetonide compositions and therapy

Patent Citations (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2801201A (en) * 1953-04-09 1957-07-30 Lincoln Lab Inc Burn treatment filling for pressure packaged dispenser
US2798836A (en) * 1954-01-18 1957-07-09 American Cyanamid Co Inhalable live virus veterinary vaccine
US2798835A (en) * 1954-01-18 1957-07-09 American Cyanamid Co Newcastle disease and infectious bronchitis vaccines and production thereof
US2959325A (en) * 1954-04-29 1960-11-08 Risdon Mfg Co Method and apparatus for dispensing dry powders
US2802772A (en) * 1954-09-09 1957-08-13 Merck & Co Inc Aerosols compositions; bomb, and process for treating flocks of chickens
US2782975A (en) * 1955-04-20 1957-02-26 American Cyanamid Co Sprayable amorphous antibiotic composition, pressurized container with same, and method of preparing
US3014844A (en) * 1957-01-31 1961-12-26 Riker Laboratories Inc Self-propelling powder dispensing compositions
US2987439A (en) * 1958-01-07 1961-06-06 William Cooper & Nephews Inc Method of applying an aerosol to the eye
US3073743A (en) * 1959-07-30 1963-01-15 Upjohn Co Antiinflammatory steroid acetonide compositions and therapy
US3028308A (en) * 1959-10-01 1962-04-03 Merck & Co Inc Dry pharmaceutical vehicle of copolymer of hydrolyzed gelatin and glyoxal, and its production
US3039929A (en) * 1960-03-17 1962-06-19 Abbott Lab Stable isoproteronol compositions

Cited By (620)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3482015A (en) * 1965-02-08 1969-12-02 Merck & Co Inc Aerosol composition of phenylephrine tartrate and the production of such
US3282791A (en) * 1965-08-17 1966-11-01 Merck & Co Inc Inhalation aerosol suspension of anhydrous disodium dexamethasone phosphate, propellents, and sorbitan trioleate
US3897779A (en) * 1973-06-27 1975-08-05 American Cyanamid Co Triamcinolone acetonide inhalation therapy
US3985868A (en) * 1973-06-27 1976-10-12 American Cyanamid Company Asthma treatment by inhalation of micronized N,N-diethyl-4-methyl-1-piperazinecarboxamide pamoate
EP0091313A3 (en) * 1982-04-05 1985-05-22 Alcon Laboratories Inc Perfluorohydrocarbons as vehicles for administering drugs
US4581225A (en) * 1984-04-25 1986-04-08 Eli Lilly And Company Sustained release intranasal formulation and method of use thereof
US5681545A (en) * 1988-12-06 1997-10-28 Riker Laboratories, Inc. Medicinal aerosol formulations
US5766573A (en) * 1988-12-06 1998-06-16 Riker Laboratories, Inc. Medicinal aerosol formulations
US5605674A (en) * 1988-12-06 1997-02-25 Riker Laboratories, Inc. Medicinal aerosol formulations
US5720940A (en) * 1988-12-06 1998-02-24 Riker Laboratories, Inc. Medicinal aerosol formulations
US5695743A (en) * 1988-12-06 1997-12-09 Riker Laboratories, Inc. Medicinal aerosol formulations
US5674473A (en) * 1988-12-06 1997-10-07 Riker Laboratories, Inc. Medicinal aerosol formulations
US5683677A (en) * 1988-12-06 1997-11-04 Riker Laboratories, Inc. Medicinal aerosol formulations
US6352684B1 (en) 1988-12-06 2002-03-05 Riker Laboratories Inc. CRC-free medicinal aerosol formulations of 1,1,1,2-tetrafluoroethane (134A) with polar adjuvant
US5439670A (en) * 1989-11-28 1995-08-08 Riker Laboratories, Inc. Medicinal aerosol formulations
US20090104127A1 (en) * 1990-02-03 2009-04-23 Boehringer Ingelheim Kg Suspension aerosol formulations of pharmaceutical products
US7160538B2 (en) 1990-02-03 2007-01-09 Boehringer Ingelheim Kg Suspension aerosol formulations of pharmaceutical products
US20050031548A1 (en) * 1990-02-03 2005-02-10 Boehringer Ingelheim Kg Suspension aerosol formulations of pharmaceutical products
US20110014134A1 (en) * 1990-02-03 2011-01-20 Boehringer Ingelheim Kg Suspension aerosol formulations of pharmaceutical products
US6306368B1 (en) 1990-11-09 2001-10-23 Glaxo Group Limited Aerosol formulation containing a particulate medicament
US5919435A (en) * 1990-11-09 1999-07-06 Glaxo Group Limited Aerosol formulation containing a particulate medicament
US5785952A (en) * 1990-11-09 1998-07-28 Glaxo Group Limited Aerosol medicament formulation having a surface coating of surfactant
US6238647B1 (en) 1991-12-12 2001-05-29 Glaxo Group Limited Aerosol formulations containing salmeterol xinafoate, an anticholinergic agent and tetrafluoroethane
US5658549A (en) * 1991-12-12 1997-08-19 Glaxo Group Limited Aerosol formulations containing propellant 134a and fluticasone propionate
US5817293A (en) * 1991-12-12 1998-10-06 Glaxo Group Limited Canister containing aerosol formulations containing P134a and particulate medicaments
US20050089477A1 (en) * 1991-12-12 2005-04-28 Glaxo Group Limited Medicaments
US5736124A (en) * 1991-12-12 1998-04-07 Glaxo Group Limited Aerosol formulations containing P134a and particulate medicament
US5922306A (en) * 1991-12-12 1999-07-13 Glaxo Group Limited Aerosol formulations containing P134a and particulate medicament
US6200549B1 (en) 1991-12-12 2001-03-13 Glaxo Group Limited Aerosol formulation containing P134a and particulate medicament
US6221339B1 (en) 1991-12-12 2001-04-24 Glaxo Group Limited Medicaments
US6893628B2 (en) 1991-12-12 2005-05-17 Glaxo Group Limited Aerosol formulations containing P134a and particulate medicament
US6251368B1 (en) 1991-12-12 2001-06-26 Glaxo Group Limited Pharmaceutical aerosol formulation containing a particulate medicament, a propellant and substantially free of a surfactant
US6303103B1 (en) 1991-12-12 2001-10-16 Glaxo Group Limited Aerosols containing salmeterol xinafoate and an anticholinergic medicament
US6306369B1 (en) 1991-12-12 2001-10-23 Glaxo Group Limited Aerosol formulations containing P134a and particulate medicament
US5683676A (en) * 1991-12-12 1997-11-04 Glaxo Group Limited Canister containing aerosol formulations containing P134a and particulate medicaments
US6333023B1 (en) 1991-12-12 2001-12-25 Glaxo Group Limited Aerosol formulation containing particulate formoterol, propellant and polar cosolvent
US5676929A (en) * 1991-12-12 1997-10-14 Glaxo Group Limited Canister containing aerosol formulations containing P134a and particulate medicaments
US5674472A (en) * 1991-12-12 1997-10-07 Glaxo Group Limited Canisters containing aerosol formulations containing P134a and fluticasone propionate
US5674471A (en) * 1991-12-12 1997-10-07 Glaxo Group Limited Aerosol formulations containing P134a and salbutamol
EP1066828B2 (en) † 1991-12-12 2006-12-06 Glaxo Group Limited Aerosol compositions
US7498020B2 (en) 1991-12-12 2009-03-03 Glaxo Group Limited Medicaments
US5744123A (en) * 1991-12-12 1998-04-28 Glaxo Group Limited Aerosol formulations containing P134a and particulate medicaments
US20030143163A1 (en) * 1991-12-12 2003-07-31 Glaxo Group Limited Medicaments
US20030165437A1 (en) * 1991-12-12 2003-09-04 Glaxo Group Limited Aerosos formulations containing P134a and particulate medicament
US20030198600A1 (en) * 1991-12-12 2003-10-23 Glaxo Group Limited Aerosol formulation containing particulate formoterol, propellant and polar cosolvent
US6919069B2 (en) 1991-12-12 2005-07-19 Glaxo Group Limited Aerosol formulation containing particulate formoterol, propellant and polar cosolvent
US20050207991A1 (en) * 1991-12-12 2005-09-22 Glaxo Group Limited Aerosol formulations containing P134a and particulate medicament
US20050232873A1 (en) * 1991-12-12 2005-10-20 Glaxo Group Limited Aerosol formulation containing particulate formoterol, propellant and polar cosolvent
US5653962A (en) * 1991-12-12 1997-08-05 Glaxo Group Limited Aerosol formulations containing P134a and particulate medicaments
US20090188491A1 (en) * 1991-12-12 2009-07-30 Glaxo Group Limited Medicaments
US7101534B1 (en) 1991-12-18 2006-09-05 3M Innovative Properties Company Suspension aerosol formulations
US6743413B1 (en) 1991-12-18 2004-06-01 3M Company Suspension aerosol formulations
US7105152B1 (en) 1991-12-18 2006-09-12 3M Innovative Properties Company Suspension aerosol formulations
US20040197273A1 (en) * 1991-12-18 2004-10-07 3M Company Suspension aerosol formulations
US5916540A (en) * 1994-10-24 1999-06-29 Glaxo Group Limited Aerosol formulations containing P134A and/or P227 and particulate medicament
US5603918A (en) * 1995-06-09 1997-02-18 Boehringer Ingelheim Pharmaceuticals, Inc. Aerosol composition of a salt of ipratropium and a salt of albuterol
US20030232876A1 (en) * 1996-08-16 2003-12-18 Pozen, Inc. Methods of treating headaches using 5-HT agonists in combination with long-acting NSAIDs
US9155496B2 (en) 1997-03-04 2015-10-13 Dexcom, Inc. Low oxygen in vivo analyte sensor
US7771352B2 (en) 1997-03-04 2010-08-10 Dexcom, Inc. Low oxygen in vivo analyte sensor
US7901354B2 (en) 1997-03-04 2011-03-08 Dexcom, Inc. Low oxygen in vivo analyte sensor
US8688188B2 (en) 1998-04-30 2014-04-01 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
US8346336B2 (en) 1998-04-30 2013-01-01 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
US8774887B2 (en) 1998-04-30 2014-07-08 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
US10478108B2 (en) 1998-04-30 2019-11-19 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
US8744545B2 (en) 1998-04-30 2014-06-03 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
US8738109B2 (en) 1998-04-30 2014-05-27 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
US8734346B2 (en) 1998-04-30 2014-05-27 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
US8734348B2 (en) 1998-04-30 2014-05-27 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
US20080076997A1 (en) * 1998-04-30 2008-03-27 Abbott Diabetes Care, Inc. Analyte monitoring device and methods of use
US8672844B2 (en) 1998-04-30 2014-03-18 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
US9326714B2 (en) 1998-04-30 2016-05-03 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
US8670815B2 (en) 1998-04-30 2014-03-11 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
US8666469B2 (en) 1998-04-30 2014-03-04 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
US8660627B2 (en) 1998-04-30 2014-02-25 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
US9072477B2 (en) 1998-04-30 2015-07-07 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
US8649841B2 (en) 1998-04-30 2014-02-11 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
US8641619B2 (en) 1998-04-30 2014-02-04 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
US8622906B2 (en) 1998-04-30 2014-01-07 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
US8617071B2 (en) 1998-04-30 2013-12-31 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
US8880137B2 (en) 1998-04-30 2014-11-04 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
US8612159B2 (en) 1998-04-30 2013-12-17 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
US8974386B2 (en) 1998-04-30 2015-03-10 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
US9066695B2 (en) 1998-04-30 2015-06-30 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
US9014773B2 (en) 1998-04-30 2015-04-21 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
US20100312078A1 (en) * 1998-04-30 2010-12-09 Abbott Diabetes Care Inc. Analyte Monitoring Device and Methods of Use
US9011331B2 (en) 1998-04-30 2015-04-21 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
US9042953B2 (en) 1998-04-30 2015-05-26 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
US7860544B2 (en) 1998-04-30 2010-12-28 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
US8597189B2 (en) 1998-04-30 2013-12-03 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
US8480580B2 (en) 1998-04-30 2013-07-09 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
US8473021B2 (en) 1998-04-30 2013-06-25 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
US8465425B2 (en) 1998-04-30 2013-06-18 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
US8409131B2 (en) 1998-04-30 2013-04-02 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
US8391945B2 (en) 1998-04-30 2013-03-05 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
US8380273B2 (en) 1998-04-30 2013-02-19 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
US8372005B2 (en) 1998-04-30 2013-02-12 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
US8366614B2 (en) 1998-04-30 2013-02-05 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
US8357091B2 (en) 1998-04-30 2013-01-22 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
US8353829B2 (en) 1998-04-30 2013-01-15 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
US8840553B2 (en) 1998-04-30 2014-09-23 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
US8346337B2 (en) 1998-04-30 2013-01-01 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
US8306598B2 (en) 1998-04-30 2012-11-06 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
US8287454B2 (en) 1998-04-30 2012-10-16 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
US8273022B2 (en) 1998-04-30 2012-09-25 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
US8275439B2 (en) 1998-04-30 2012-09-25 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
US7869853B1 (en) 1998-04-30 2011-01-11 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
US8265726B2 (en) 1998-04-30 2012-09-11 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
US8260392B2 (en) 1998-04-30 2012-09-04 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
US8255031B2 (en) 1998-04-30 2012-08-28 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
US8235896B2 (en) 1998-04-30 2012-08-07 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
US9066694B2 (en) 1998-04-30 2015-06-30 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
US8231532B2 (en) 1998-04-30 2012-07-31 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
US8226558B2 (en) 1998-04-30 2012-07-24 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
US8226557B2 (en) 1998-04-30 2012-07-24 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
US8226555B2 (en) 1998-04-30 2012-07-24 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
US8224413B2 (en) 1998-04-30 2012-07-17 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
US8177716B2 (en) 1998-04-30 2012-05-15 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
US8175673B2 (en) 1998-04-30 2012-05-08 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
US8162829B2 (en) 1998-04-30 2012-04-24 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
US7885699B2 (en) 1998-04-30 2011-02-08 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
US9066697B2 (en) 1998-04-30 2015-06-30 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
US20090181100A1 (en) * 1998-11-12 2009-07-16 Elan Pharma International Ltd Dry powder aerosols of Nanoparticulate drugs
US8124057B2 (en) * 1998-11-12 2012-02-28 Alkermes Pharma Ireland Limited Propellant-based nanoparticulate dry powder aerosols and method of making
US20040157815A1 (en) * 1999-09-11 2004-08-12 Smithkline Beecham Corporation Pharmaceutical formulation of fluticasone propionate
US20030059474A1 (en) * 1999-10-18 2003-03-27 Scott Terrence L. Sustained release microspheres
US20050048001A1 (en) * 1999-11-23 2005-03-03 Cripps Alan Leslie Pharmaceutical formulations of salmeterol
US20030032632A1 (en) * 1999-12-24 2003-02-13 Crispps Leslie Alan Pharmaceutical aerosol formulation of salmeterol and fluticasone propionate
US20090142407A1 (en) * 2000-09-01 2009-06-04 Meda Pharama Gmbh & Co. Kg Solid peptide preparations for inhalation and their preparation
US7374782B2 (en) 2000-10-27 2008-05-20 Baxter International Inc. Production of microspheres
US8668645B2 (en) 2001-01-02 2014-03-11 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
US8652043B2 (en) 2001-01-02 2014-02-18 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
US9498159B2 (en) 2001-01-02 2016-11-22 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
US9011332B2 (en) 2001-01-02 2015-04-21 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
US9610034B2 (en) 2001-01-02 2017-04-04 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
US9477811B2 (en) 2001-04-02 2016-10-25 Abbott Diabetes Care Inc. Blood glucose tracking apparatus and methods
US7976778B2 (en) 2001-04-02 2011-07-12 Abbott Diabetes Care Inc. Blood glucose tracking apparatus
US8268243B2 (en) 2001-04-02 2012-09-18 Abbott Diabetes Care Inc. Blood glucose tracking apparatus and methods
US8765059B2 (en) 2001-04-02 2014-07-01 Abbott Diabetes Care Inc. Blood glucose tracking apparatus
US8236242B2 (en) 2001-04-02 2012-08-07 Abbott Diabetes Care Inc. Blood glucose tracking apparatus and methods
US7445768B2 (en) 2001-05-24 2008-11-04 Alexza Pharmaceuticals, Inc. Delivery of sedative-hypnotics through an inhalation route
US7022312B2 (en) 2001-05-24 2006-04-04 Alexza Pharmaceuticals, Inc. Delivery of antiemetics through an inhalation route
US20040170572A1 (en) * 2001-05-24 2004-09-02 Alexza Molecular Delivery Corporation Delivery of rizatriptan or zolmitriptan through an inhalation route
US20040170573A1 (en) * 2001-05-24 2004-09-02 Alexza Molecular Delivery Corporation Delivery of sumatriptan, frovatriptan or naratriptan through an inhalation route
US20040170570A1 (en) * 2001-05-24 2004-09-02 Alexza Molecular Delivery Corporation Delivery of rizatriptan or zolmitriptan through an inhalation route
US20040185008A1 (en) * 2001-05-24 2004-09-23 Alexza Molecular Delivery Corporation Delivery of compounds for the treatment of parkinsons through an inhalation route
US20040185003A1 (en) * 2001-05-24 2004-09-23 Alexza Molecular Delivery Corporation Delivery of alprazolam, estazolam, midazolam or triazolam through an inhalation route
US20040185005A1 (en) * 2001-05-24 2004-09-23 Alexza Molecular Delivery Corporation Delivery of antiemetics through an inhalation route
US20040185001A1 (en) * 2001-05-24 2004-09-23 Alexza Molecular Delivery Corporation Delivery of physiologically active compounds through an inhalation route
US20040185007A1 (en) * 2001-05-24 2004-09-23 Alexza Molecular Delivery Corporation Delivery of compounds for the treatment of Parkinsons through an inhalation route
US7169378B2 (en) 2001-05-24 2007-01-30 Alexza Pharmaceuticals, Inc. Delivery of opioids through an inhalation route
US20040167228A1 (en) * 2001-05-24 2004-08-26 Alexza Molecular Delivery Corporation Delivery of beta-blockers through an inhalation route
US20040186130A1 (en) * 2001-05-24 2004-09-23 Alexza Molecular Delivery Corporation Delivery of muscle relaxants through an inhalation route
US20040126326A1 (en) * 2001-05-24 2004-07-01 Alexza Molecular Delivery Corporation Delivery of antidepressants through an inhalation route
US7442368B2 (en) 2001-05-24 2008-10-28 Alexza Pharmaceuticals, Inc. Delivery of stimulants through an inhalation route
US20060286042A1 (en) * 2001-05-24 2006-12-21 Alexza Pharmaceuticals, Inc. Delivery of sedative-hypnotics through an inhalation route
US7449173B2 (en) 2001-05-24 2008-11-11 Alexza Pharmaceuticals, Inc. Delivery of alprazolam, estazolam, midazolam or triazolam through an inhalation route
US7449172B2 (en) 2001-05-24 2008-11-11 Alexza Pharmaceuticals, Inc. Delivery of antiemetics through an inhalation route
US7449175B2 (en) 2001-05-24 2008-11-11 Alexza Pharmaceuticals, Inc. Delivery of erectile dysfunction drugs through an inhalation route
US7449174B2 (en) 2001-05-24 2008-11-11 Alexza Pharmaceuticals, Inc. Delivery of analgesics through an inhalation route
US20040184996A1 (en) * 2001-05-24 2004-09-23 Alexza Molecular Delivery Corporation Delivery of nonsteroidal antiinflammatory drugs through an inhalation route
US20040185006A1 (en) * 2001-05-24 2004-09-23 Alexza Molecular Delivery Corporation Delivery of stimulants through an inhalation route
US20040185000A1 (en) * 2001-05-24 2004-09-23 Alexza Molecular Delivery Corporation Delivery of antihistamines through an inhalation route
US7465435B2 (en) 2001-05-24 2008-12-16 Alexza Pharmaceuticals, Inc. Delivery of beta-blockers through an inhalation route
US7465437B2 (en) 2001-05-24 2008-12-16 Alexza Pharmaceuticals, Inc. Delivery of anti-migraine compounds through an inhalation route
US7465436B2 (en) 2001-05-24 2008-12-16 Alexza Pharmaceuticals, Inc. Delivery of compounds for the treatment of Parkinson's through an inhalation route
US7468179B2 (en) 2001-05-24 2008-12-23 Alexza Pharmaceuticals, Inc. Delivery of opioids through an inhalation route
US20040161385A1 (en) * 2001-05-24 2004-08-19 Alexza Molecular Delivery Corporation Delivery of beta-blockers through an inhalation route
US7485285B2 (en) 2001-05-24 2009-02-03 Alexza Pharmaceuticals, Inc. Delivery of antidepressants through an inhalation route
US7491047B2 (en) 2001-05-24 2009-02-17 Alexza Pharmaceuticals, Inc. Delivery of antihistamines through an inhalation route
US7498019B2 (en) 2001-05-24 2009-03-03 Alexza Pharmaceuticals, Inc. Delivery of compounds for the treatment of headache through an inhalation route
US20040184999A1 (en) * 2001-05-24 2004-09-23 Alexza Molecular Delivery Corporation Delivery of anti-migraine compounds through an inhalation route
US7507397B2 (en) 2001-05-24 2009-03-24 Alexza Pharmaceuticals, Inc. Delivery of muscle relaxants through an inhalation route
US7510702B2 (en) 2001-05-24 2009-03-31 Alexza Pharmaceuticals, Inc. Delivery of nonsteroidal antiinflammatory drugs through an inhalation route
US20040185004A1 (en) * 2001-05-24 2004-09-23 Alexza Molecular Delivery Corporation Delivery of erectile dysfunction drugs through an inhalation route
US20060233719A1 (en) * 2001-05-24 2006-10-19 Alexza Pharmaceuticals, Inc. Delivery of antidepressants through an inhalation route
US7524484B2 (en) 2001-05-24 2009-04-28 Alexza Pharmaceuticals, Inc. Delivery of diphenhydramine through an inhalation route
US7070765B2 (en) 2001-05-24 2006-07-04 Alexza Pharmaceuticals, Inc. Delivery of drug esters through an inhalation route
US7070762B2 (en) 2001-05-24 2006-07-04 Alexza Pharmaceuticals, Inc. Delivery of analgesics through an inhalation route
US20040191180A1 (en) * 2001-05-24 2004-09-30 Alexza Molecular Delivery Corporation Delivery of compounds for the treatment of migraine through an inhalation route
US7115250B2 (en) 2001-05-24 2006-10-03 Alexza Pharmaceuticals, Inc. Delivery of erectile dysfunction drugs through an inhalation route
US20040191183A1 (en) * 2001-05-24 2004-09-30 Alexza Molecular Delivery Corporation Delivery of antiemetics through an inhalation route
US20040191182A1 (en) * 2001-05-24 2004-09-30 Alexza Molecular Delivery Corporation Delivery of analgesics through an inhalation route
US7108847B2 (en) 2001-05-24 2006-09-19 Alexza Pharmaceuticals, Inc. Delivery of muscle relaxants through an inhalation route
US20040191179A1 (en) * 2001-05-24 2004-09-30 Alexza Molecular Delivery Corporation Delivery of antidepressants through an inhalation route
US7094392B2 (en) 2001-05-24 2006-08-22 Alexza Pharmaceuticals, Inc. Delivery of antihistamines through an inhalation route
WO2002094245A1 (en) * 2001-05-24 2002-11-28 Alexza Molecular Delivery Corporation Delivery of antihistamines through an inhalation route
US20040191181A1 (en) * 2001-05-24 2004-09-30 Alexza Molecular Delivery Corporation Delivery of diphenhydramine through an inhalation route
US20040156788A1 (en) * 2001-05-24 2004-08-12 Alexza Molecular Delivery Corporation Delivery of erectile dysfunction drugs through an inhalation route
US7585493B2 (en) 2001-05-24 2009-09-08 Alexza Pharmaceuticals, Inc. Thin-film drug delivery article and method of use
US10350157B2 (en) 2001-05-24 2019-07-16 Alexza Pharmaceuticals, Inc. Drug condensation aerosols and kits
US20040202617A1 (en) * 2001-05-24 2004-10-14 Alexza Molecular Delivery Corporation Delivery of opioids through an inhalation route
US7601337B2 (en) 2001-05-24 2009-10-13 Alexza Pharmaceuticals, Inc. Delivery of antipsychotics through an inhalation route
US20040127481A1 (en) * 2001-05-24 2004-07-01 Alexza Molecular Delivery Corporation Delivery of anti-migraine compounds through an inhalation route
US7070761B2 (en) 2001-05-24 2006-07-04 Alexza Pharmaceuticals, Inc. Delivery of nonsteroidal antiinflammatory drugs through an inhalation route
US7078018B2 (en) 2001-05-24 2006-07-18 Alexza Pharmaceuticals, Inc. Delivery of opioids through an inhalation route
US7070766B2 (en) 2001-05-24 2006-07-04 Alexza Pharmaceuticals, Inc. Delivery of physiologically active compounds through an inhalation route
US7070763B2 (en) 2001-05-24 2006-07-04 Alexza Pharmaceuticals, Inc. Delivery of diphenhydramine through an inhalation route
US20040127490A1 (en) * 2001-05-24 2004-07-01 Alexza Molecular Delivery Corporation Delivery of alprazolam, estazolam midazolam or triazolam through an inhalation route
US20040126328A1 (en) * 2001-05-24 2004-07-01 Alexza Molecular Delivery Corporation Delivery of compounds for the treatment of migraine through an inhalation route
US7067114B2 (en) 2001-05-24 2006-06-27 Alexza Pharmaceuticals, Inc. Delivery of antihistamines through an inhalation route
US7090830B2 (en) 2001-05-24 2006-08-15 Alexza Pharmaceuticals, Inc. Drug condensation aerosols and kits
US20040126327A1 (en) * 2001-05-24 2004-07-01 Alexza Molecular Delivery Corporation Delivery of nonsteroidal antiinflammatory drugs through an inhalation route
US9211382B2 (en) 2001-05-24 2015-12-15 Alexza Pharmaceuticals, Inc. Drug condensation aerosols and kits
US7063832B2 (en) 2001-05-24 2006-06-20 Alexza Pharmaceuticals, Inc. Delivery of muscle relaxants through an inhalation route
US7005122B2 (en) 2001-05-24 2006-02-28 Alexza Pharmaceutical, Inc. Delivery of sumatriptan, frovatriptan or naratriptan through an inhalation route
US7087217B2 (en) 2001-05-24 2006-08-08 Alexza Pharmaceuticals, Inc. Delivery of nonsteroidal antiinflammatory drugs through an inhalation route
US7005121B2 (en) 2001-05-24 2006-02-28 Alexza Pharmaceuticals, Inc. Delivery of compounds for the treatment of migraine through an inhalation route
US7087216B2 (en) 2001-05-24 2006-08-08 Rabinowitz Joshua D Delivery of sedative-hypnotics through an inhalation route
US7008616B2 (en) 2001-05-24 2006-03-07 Alexza Pharmaceuticals, Inc. Delivery of stimulants through an inhalation route
US7078017B2 (en) 2001-05-24 2006-07-18 Alexza Pharmaceuticals, Inc. Delivery of sedative-hypnotics through an inhalation route
US7078020B2 (en) 2001-05-24 2006-07-18 Alexza Pharmaceuticals, Inc. Delivery of antipsychotics through an inhalation route
US20040126329A1 (en) * 2001-05-24 2004-07-01 Alexza Molecular Delivery Corporation Delivery of analgesics through an inhalation route
US7008615B2 (en) 2001-05-24 2006-03-07 Alexza Pharmaceuticals, Inc. Delivery of anti-migraine compounds through an inhalation route
US7011820B2 (en) 2001-05-24 2006-03-14 Alexza Pharmaceuticals, Inc. Delivery of compounds for the treatment of Parkinsons through an inhalation route
US7078019B2 (en) 2001-05-24 2006-07-18 Alexza Pharmaceuticals, Inc. Delivery of drug esters through an inhalation route
US7011819B2 (en) 2001-05-24 2006-03-14 Alexza Pharmaceuticals, Inc. Delivery of rizatriptan or zolmitriptan through an inhalation route
US7014840B2 (en) 2001-05-24 2006-03-21 Alexza Pharmaceuticals, Inc. Delivery of sumatriptan, frovatriptan or naratriptan through an inhalation route
US7014841B2 (en) 2001-05-24 2006-03-21 Alexza Pharmaceuticals, Inc. Delivery of antiemetics through an inhalation route
US7018619B2 (en) 2001-05-24 2006-03-28 Alexza Pharmaceuticals, Inc. Delivery of alprazolam, estazolam midazolam or triazolam through an inhalation route
US7018620B2 (en) 2001-05-24 2006-03-28 Alexza Pharmaceuticals, Inc. Delivery of beta-blockers through an inhalation route
US6740308B2 (en) 2001-05-24 2004-05-25 Alexza Molecular Delivery Corporation Delivery of antihistamines through an inhalation route
US7018621B2 (en) 2001-05-24 2006-03-28 Alexza Pharmaceuticals, Inc. Delivery of rizatriptan or zolmitriptan through an inhalation route
US6994843B2 (en) 2001-05-24 2006-02-07 Alexza Pharmaceuticals, Inc. Delivery of stimulants through an inhalation route
US7029658B2 (en) 2001-05-24 2006-04-18 Alexza Pharmaceuticals, Inc. Delivery of antidepressants through an inhalation route
US9440034B2 (en) 2001-05-24 2016-09-13 Alexza Pharmaceuticals, Inc. Drug condensation aerosols and kits
US7063831B2 (en) 2001-05-24 2006-06-20 Alexza Pharmaceuticals, Inc. Delivery of erectile dysfunction drugs through an inhalation route
US7033575B2 (en) 2001-05-24 2006-04-25 Alexza Pharmaceuticals, Inc. Delivery of physiologically active compounds through an inhalation route
US8235037B2 (en) 2001-05-24 2012-08-07 Alexza Pharmaceuticals, Inc. Drug condensation aerosols and kits
US7045118B2 (en) 2001-05-24 2006-05-16 Alexza Pharmaceuticals, Inc. Delivery of compounds for the treatment of migraine through an inhalation route
US7048909B2 (en) 2001-05-24 2006-05-23 Alexza Pharmaceuticals, Inc. Delivery of beta-blockers through an inhalation route
US7645442B2 (en) 2001-05-24 2010-01-12 Alexza Pharmaceuticals, Inc. Rapid-heating drug delivery article and method of use
US7052680B2 (en) 2001-05-24 2006-05-30 Alexza Pharmaceuticals, Inc. Delivery of compounds for the treatment of Parkinsons through an inhalation route
US7052679B2 (en) 2001-05-24 2006-05-30 Alexza Pharmaceuticals, Inc. Delivery of antipsychotics through an inhalation route
US7060255B2 (en) 2001-05-24 2006-06-13 Alexza Pharmaceuticals, Inc. Delivery of alprazolam, estazolam, midazolam or triazolam through an inhalation route
US7060254B2 (en) 2001-05-24 2006-06-13 Alexza Pharmaceuticals, Inc. Delivery of antidepressants through an inhalation route
US7988952B2 (en) 2001-05-24 2011-08-02 Alexza Pharmaceuticals, Inc. Delivery of drug esters through an inhalation route
US7070764B2 (en) 2001-05-24 2006-07-04 Alexza Pharmaceuticals, Inc. Delivery of analgesics through an inhalation route
US8173107B2 (en) 2001-05-24 2012-05-08 Alexza Pharmaceuticals, Inc. Delivery of antipsychotics through an inhalation route
US7063830B2 (en) 2001-05-24 2006-06-20 Alexza Pharmaceuticals, Inc. Delivery of anti-migraine compounds through an inhalation route
US9439907B2 (en) 2001-06-05 2016-09-13 Alexza Pharmaceutical, Inc. Method of forming an aerosol for inhalation delivery
US7942147B2 (en) 2001-06-05 2011-05-17 Alexza Pharmaceuticals, Inc. Aerosol forming device for use in inhalation therapy
US9687487B2 (en) 2001-06-05 2017-06-27 Alexza Pharmaceuticals, Inc. Aerosol forming device for use in inhalation therapy
US9308208B2 (en) 2001-06-05 2016-04-12 Alexza Pharmaceuticals, Inc. Aerosol generating method and device
US7766013B2 (en) 2001-06-05 2010-08-03 Alexza Pharmaceuticals, Inc. Aerosol generating method and device
US8955512B2 (en) 2001-06-05 2015-02-17 Alexza Pharmaceuticals, Inc. Method of forming an aerosol for inhalation delivery
US8074644B2 (en) 2001-06-05 2011-12-13 Alexza Pharmaceuticals, Inc. Method of forming an aerosol for inhalation delivery
US7537009B2 (en) 2001-06-05 2009-05-26 Alexza Pharmaceuticals, Inc. Method of forming an aerosol for inhalation delivery
US11065400B2 (en) 2001-06-05 2021-07-20 Alexza Pharmaceuticals, Inc. Aerosol forming device for use in inhalation therapy
EP1406592A4 (en) * 2001-07-18 2010-03-17 Aeropharm Technology Inc A salt/ion pair medicinal aerosol formulation
US20030064033A1 (en) * 2001-08-16 2003-04-03 Brown Larry R. Propellant-based microparticle formulations
WO2003015750A1 (en) * 2001-08-16 2003-02-27 Baxter International, Inc. Propellant-based microparticle formulations
EP1944016A1 (en) 2001-08-16 2008-07-16 Baxter International Inc. Propellant-based microparticle formulatons
US7087218B2 (en) 2001-11-09 2006-08-08 Alexza Pharmaceuticals, Inc. Delivery of diazepam through an inhalation route
US20060269486A1 (en) * 2001-11-09 2006-11-30 Alexza Pharmaceuticals, Inc. Delivery of diazepam through an inhalation route
US20040170571A1 (en) * 2001-11-09 2004-09-02 Alexza Molecular Delivery Corporation Delivery of diazepam through an inhalation route
US7470421B2 (en) 2001-11-09 2008-12-30 Alexza Pharmaceuticals, Inc Delivery of diazepam through an inhalation route
US7045119B2 (en) 2001-11-09 2006-05-16 Alexza Pharmaceuticals, Inc. Delivery of diazepam through an inhalation route
US20040171609A1 (en) * 2001-11-09 2004-09-02 Alexza Molecular Delivery Corporation Delivery of diazepam through an inhalation route
US9282925B2 (en) 2002-02-12 2016-03-15 Dexcom, Inc. Systems and methods for replacing signal artifacts in a glucose sensor data stream
US20080279949A1 (en) * 2002-03-20 2008-11-13 Elan Pharma International Ltd. Nanoparticulate compositions of angiogenesis inhibitors
US20080107741A1 (en) * 2002-03-20 2008-05-08 Elan Pharma International Ltd. Nanoparticulate compositions of angiogenesis inhibitors
US8080236B2 (en) 2002-04-17 2011-12-20 Nektar Therapeutics Uk, Ltd Particulate materials
US9616060B2 (en) 2002-04-17 2017-04-11 Nektar Therapeutics Particulate materials
US8828359B2 (en) 2002-04-17 2014-09-09 Nektar Therapeutics Particulate materials
US8470301B2 (en) 2002-04-17 2013-06-25 Nektar Therapeutics Particulate materials
US7582284B2 (en) 2002-04-17 2009-09-01 Nektar Therapeutics Particulate materials
US10251881B2 (en) 2002-04-17 2019-04-09 Nektar Therapeutics Particulate materials
US7458374B2 (en) 2002-05-13 2008-12-02 Alexza Pharmaceuticals, Inc. Method and apparatus for vaporizing a compound
US7987846B2 (en) 2002-05-13 2011-08-02 Alexza Pharmaceuticals, Inc. Method and apparatus for vaporizing a compound
US8003080B2 (en) 2002-05-13 2011-08-23 Alexza Pharmaceuticals, Inc. Delivery of drug amines through an inhalation route
US7550133B2 (en) 2002-11-26 2009-06-23 Alexza Pharmaceuticals, Inc. Respiratory drug condensation aerosols and methods of making and using them
US7981401B2 (en) 2002-11-26 2011-07-19 Alexza Pharmaceuticals, Inc. Diuretic aerosols and methods of making and using them
US8288372B2 (en) 2002-11-26 2012-10-16 Alexza Pharmaceuticals, Inc. Method for treating headache with loxapine
US8506935B2 (en) 2002-11-26 2013-08-13 Alexza Pharmaceuticals, Inc. Respiratory drug condensation aerosols and methods of making and using them
US7913688B2 (en) 2002-11-27 2011-03-29 Alexza Pharmaceuticals, Inc. Inhalation device for producing a drug aerosol
US8387612B2 (en) 2003-05-21 2013-03-05 Alexza Pharmaceuticals, Inc. Self-contained heating unit and drug-supply unit employing same
US8991387B2 (en) 2003-05-21 2015-03-31 Alexza Pharmaceuticals, Inc. Self-contained heating unit and drug-supply unit employing same
US9370629B2 (en) 2003-05-21 2016-06-21 Alexza Pharmaceuticals, Inc. Self-contained heating unit and drug-supply unit employing same
US7896809B2 (en) 2003-07-25 2011-03-01 Dexcom, Inc. Dual electrode system for a continuous analyte sensor
US8260393B2 (en) 2003-07-25 2012-09-04 Dexcom, Inc. Systems and methods for replacing signal data artifacts in a glucose sensor data stream
US8423113B2 (en) 2003-07-25 2013-04-16 Dexcom, Inc. Systems and methods for processing sensor data
US8676287B2 (en) 2003-08-01 2014-03-18 Dexcom, Inc. System and methods for processing analyte sensor data
US8052601B2 (en) 2003-08-01 2011-11-08 Dexcom, Inc. System and methods for processing analyte sensor data
US7986986B2 (en) 2003-08-01 2011-07-26 Dexcom, Inc. System and methods for processing analyte sensor data
US8886273B2 (en) 2003-08-01 2014-11-11 Dexcom, Inc. Analyte sensor
US8808182B2 (en) 2003-08-01 2014-08-19 Dexcom, Inc. System and methods for processing analyte sensor data
US8915849B2 (en) 2003-08-01 2014-12-23 Dexcom, Inc. Transcutaneous analyte sensor
US7979104B2 (en) 2003-08-01 2011-07-12 Dexcom, Inc. System and methods for processing analyte sensor data
US8801612B2 (en) 2003-08-01 2014-08-12 Dexcom, Inc. System and methods for processing analyte sensor data
US8000901B2 (en) 2003-08-01 2011-08-16 Dexcom, Inc. Transcutaneous analyte sensor
US7959569B2 (en) 2003-08-01 2011-06-14 Dexcom, Inc. System and methods for processing analyte sensor data
US8275437B2 (en) 2003-08-01 2012-09-25 Dexcom, Inc. Transcutaneous analyte sensor
US7955261B2 (en) 2003-08-01 2011-06-07 Dexcom, Inc. System and methods for processing analyte sensor data
US8160669B2 (en) 2003-08-01 2012-04-17 Dexcom, Inc. Transcutaneous analyte sensor
US8285354B2 (en) 2003-08-01 2012-10-09 Dexcom, Inc. System and methods for processing analyte sensor data
US8986209B2 (en) 2003-08-01 2015-03-24 Dexcom, Inc. Transcutaneous analyte sensor
US8788007B2 (en) 2003-08-01 2014-07-22 Dexcom, Inc. Transcutaneous analyte sensor
US8788006B2 (en) 2003-08-01 2014-07-22 Dexcom, Inc. System and methods for processing analyte sensor data
US8788008B2 (en) 2003-08-01 2014-07-22 Dexcom, Inc. System and methods for processing analyte sensor data
US8290562B2 (en) 2003-08-01 2012-10-16 Dexcom, Inc. System and methods for processing analyte sensor data
US8771187B2 (en) 2003-08-01 2014-07-08 Dexcom, Inc. System and methods for processing analyte sensor data
US8774888B2 (en) 2003-08-01 2014-07-08 Dexcom, Inc. System and methods for processing analyte sensor data
US8761856B2 (en) 2003-08-01 2014-06-24 Dexcom, Inc. System and methods for processing analyte sensor data
US8700117B2 (en) 2003-08-01 2014-04-15 Dexcom, Inc. System and methods for processing analyte sensor data
US7933639B2 (en) 2003-08-01 2011-04-26 Dexcom, Inc. System and methods for processing analyte sensor data
US8311749B2 (en) 2003-08-01 2012-11-13 Dexcom, Inc. Transcutaneous analyte sensor
US8321149B2 (en) 2003-08-01 2012-11-27 Dexcom, Inc. Transcutaneous analyte sensor
US8332008B2 (en) 2003-08-01 2012-12-11 Dexcom, Inc. System and methods for processing analyte sensor data
US8622905B2 (en) 2003-08-01 2014-01-07 Dexcom, Inc. System and methods for processing analyte sensor data
US10786185B2 (en) 2003-08-01 2020-09-29 Dexcom, Inc. System and methods for processing analyte sensor data
US8206297B2 (en) 2003-08-01 2012-06-26 Dexcom, Inc. System and methods for processing analyte sensor data
US7925321B2 (en) 2003-08-01 2011-04-12 Dexcom, Inc. System and methods for processing analyte sensor data
US7583990B2 (en) 2003-08-01 2009-09-01 Dexcom, Inc. System and methods for processing analyte sensor data
US7914450B2 (en) 2003-08-01 2011-03-29 Dexcom, Inc. System and methods for processing analyte sensor data
US7599726B2 (en) 2003-08-01 2009-10-06 Dexcom, Inc. System and methods for processing analyte sensor data
US8369919B2 (en) 2003-08-01 2013-02-05 Dexcom, Inc. Systems and methods for processing sensor data
US8588882B2 (en) 2003-08-01 2013-11-19 Dexcom, Inc. System and methods for processing analyte sensor data
US7778680B2 (en) 2003-08-01 2010-08-17 Dexcom, Inc. System and methods for processing analyte sensor data
US8548553B2 (en) 2003-08-01 2013-10-01 Dexcom, Inc. System and methods for processing analyte sensor data
US7797028B2 (en) 2003-08-01 2010-09-14 Dexcom, Inc. System and methods for processing analyte sensor data
US7826981B2 (en) 2003-08-01 2010-11-02 Dexcom, Inc. System and methods for processing analyte sensor data
US8060173B2 (en) 2003-08-01 2011-11-15 Dexcom, Inc. System and methods for processing analyte sensor data
US9895089B2 (en) 2003-08-01 2018-02-20 Dexcom, Inc. System and methods for processing analyte sensor data
US8394021B2 (en) 2003-08-01 2013-03-12 Dexcom, Inc. System and methods for processing analyte sensor data
US8845536B2 (en) 2003-08-01 2014-09-30 Dexcom, Inc. Transcutaneous analyte sensor
US8442610B2 (en) 2003-08-01 2013-05-14 Dexcom, Inc. System and methods for processing analyte sensor data
US8428679B2 (en) 2003-08-01 2013-04-23 Dexcom, Inc. System and methods for processing analyte sensor data
US9247901B2 (en) 2003-08-22 2016-02-02 Dexcom, Inc. Systems and methods for replacing signal artifacts in a glucose sensor data stream
US8657747B2 (en) 2003-08-22 2014-02-25 Dexcom, Inc. Systems and methods for processing analyte sensor data
US8128562B2 (en) 2003-08-22 2012-03-06 Dexcom, Inc. Systems and methods for replacing signal artifacts in a glucose sensor data stream
US8843187B2 (en) 2003-08-22 2014-09-23 Dexcom, Inc. Systems and methods for replacing signal artifacts in a glucose sensor data stream
US8435179B2 (en) 2003-08-22 2013-05-07 Dexcom, Inc. Systems and methods for replacing signal artifacts in a glucose sensor data stream
US8412301B2 (en) 2003-08-22 2013-04-02 Dexcom, Inc. Systems and methods for replacing signal artifacts in a glucose sensor data stream
US8292810B2 (en) 2003-08-22 2012-10-23 Dexcom, Inc. Systems and methods for replacing signal artifacts in a glucose sensor data stream
US9510782B2 (en) 2003-08-22 2016-12-06 Dexcom, Inc. Systems and methods for replacing signal artifacts in a glucose sensor data stream
US8010174B2 (en) 2003-08-22 2011-08-30 Dexcom, Inc. Systems and methods for replacing signal artifacts in a glucose sensor data stream
US8821400B2 (en) 2003-08-22 2014-09-02 Dexcom, Inc. Systems and methods for replacing signal artifacts in a glucose sensor data stream
US8005525B2 (en) 2003-08-22 2011-08-23 Dexcom, Inc. Systems and methods for replacing signal artifacts in a glucose sensor data stream
US8672845B2 (en) 2003-08-22 2014-03-18 Dexcom, Inc. Systems and methods for processing analyte sensor data
US8150488B2 (en) 2003-08-22 2012-04-03 Dexcom, Inc. Systems and methods for replacing signal artifacts in a glucose sensor data stream
US9585607B2 (en) 2003-08-22 2017-03-07 Dexcom, Inc. Systems and methods for replacing signal artifacts in a glucose sensor data stream
US9750460B2 (en) 2003-08-22 2017-09-05 Dexcom, Inc. Systems and methods for replacing signal artifacts in a glucose sensor data stream
US8491474B2 (en) 2003-08-22 2013-07-23 Dexcom, Inc. Systems and methods for replacing signal artifacts in a glucose sensor data stream
US8229536B2 (en) 2003-08-22 2012-07-24 Dexcom, Inc. Systems and methods for replacing signal artifacts in a glucose sensor data stream
US8073520B2 (en) 2003-08-22 2011-12-06 Dexcom, Inc. Systems and methods for replacing signal artifacts in a glucose sensor data stream
US8812073B2 (en) 2003-08-22 2014-08-19 Dexcom, Inc. Systems and methods for replacing signal artifacts in a glucose sensor data stream
US7998071B2 (en) 2003-08-22 2011-08-16 Dexcom, Inc. Systems and methods for replacing signal artifacts in a glucose sensor data stream
US8795177B2 (en) 2003-08-22 2014-08-05 Dexcom, Inc. Systems and methods for replacing signal artifacts in a glucose sensor data stream
US8790260B2 (en) 2003-08-22 2014-07-29 Dexcom, Inc. Systems and methods for replacing signal artifacts in a glucose sensor data stream
US11589823B2 (en) 2003-08-22 2023-02-28 Dexcom, Inc. Systems and methods for replacing signal artifacts in a glucose sensor data stream
US9149219B2 (en) 2003-08-22 2015-10-06 Dexcom, Inc. Systems and methods for replacing signal artifacts in a glucose sensor data stream
US8233959B2 (en) 2003-08-22 2012-07-31 Dexcom, Inc. Systems and methods for processing analyte sensor data
US20100179407A1 (en) * 2003-08-22 2010-07-15 Dexcom, Inc. Systems and methods for replacing signal artifacts in a glucose sensor data stream
US8073519B2 (en) 2003-08-22 2011-12-06 Dexcom, Inc. Systems and methods for replacing signal artifacts in a glucose sensor data stream
US11559260B2 (en) 2003-08-22 2023-01-24 Dexcom, Inc. Systems and methods for processing analyte sensor data
US9649069B2 (en) 2003-08-22 2017-05-16 Dexcom, Inc. Systems and methods for replacing signal artifacts in a glucose sensor data stream
US8167801B2 (en) 2003-08-22 2012-05-01 Dexcom, Inc. Systems and methods for replacing signal artifacts in a glucose sensor data stream
US8777853B2 (en) 2003-08-22 2014-07-15 Dexcom, Inc. Systems and methods for replacing signal artifacts in a glucose sensor data stream
US7935057B2 (en) 2003-08-22 2011-05-03 Dexcom, Inc. Systems and methods for replacing signal artifacts in a glucose sensor data stream
US9724045B1 (en) 2003-08-22 2017-08-08 Dexcom, Inc. Systems and methods for replacing signal artifacts in a glucose sensor data stream
US8346338B2 (en) 2003-08-22 2013-01-01 Dexcom, Inc. System and methods for replacing signal artifacts in a glucose sensor data stream
US9427183B2 (en) 2003-08-22 2016-08-30 Dexcom, Inc. Systems and methods for replacing signal artifacts in a glucose sensor data stream
US8195265B2 (en) 2003-08-22 2012-06-05 Dexcom, Inc. Systems and methods for replacing signal artifacts in a glucose sensor data stream
US9420968B2 (en) 2003-08-22 2016-08-23 Dexcom, Inc. Systems and methods for replacing signal artifacts in a glucose sensor data stream
US8282550B2 (en) 2003-11-19 2012-10-09 Dexcom, Inc. Integrated receiver for continuous analyte sensor
US11564602B2 (en) 2003-11-19 2023-01-31 Dexcom, Inc. Integrated receiver for continuous analyte sensor
US7927274B2 (en) 2003-11-19 2011-04-19 Dexcom, Inc. Integrated receiver for continuous analyte sensor
US9538946B2 (en) 2003-11-19 2017-01-10 Dexcom, Inc. Integrated receiver for continuous analyte sensor
US7519408B2 (en) 2003-11-19 2009-04-14 Dexcom, Inc. Integrated receiver for continuous analyte sensor
US8386004B2 (en) 2003-12-05 2013-02-26 Dexcom, Inc. Calibration techniques for a continuous analyte sensor
US7715893B2 (en) 2003-12-05 2010-05-11 Dexcom, Inc. Calibration techniques for a continuous analyte sensor
US7917186B2 (en) 2003-12-05 2011-03-29 Dexcom, Inc. Calibration techniques for a continuous analyte sensor
USRE44695E1 (en) 2003-12-05 2014-01-07 Dexcom, Inc. Dual electrode system for a continuous analyte sensor
US11000215B1 (en) 2003-12-05 2021-05-11 Dexcom, Inc. Analyte sensor
US8483793B2 (en) 2003-12-05 2013-07-09 Dexcom, Inc. Dual electrode system for a continuous analyte sensor
US8249684B2 (en) 2003-12-05 2012-08-21 Dexcom, Inc. Calibration techniques for a continuous analyte sensor
US11633133B2 (en) 2003-12-05 2023-04-25 Dexcom, Inc. Dual electrode system for a continuous analyte sensor
US8160671B2 (en) 2003-12-05 2012-04-17 Dexcom, Inc. Calibration techniques for a continuous analyte sensor
US11020031B1 (en) 2003-12-05 2021-06-01 Dexcom, Inc. Analyte sensor
US8287453B2 (en) 2003-12-05 2012-10-16 Dexcom, Inc. Analyte sensor
US8428678B2 (en) 2003-12-05 2013-04-23 Dexcom, Inc. Calibration techniques for a continuous analyte sensor
US9192328B2 (en) 2003-12-09 2015-11-24 Dexcom, Inc. Signal processing for continuous analyte sensor
US8005524B2 (en) 2003-12-09 2011-08-23 Dexcom, Inc. Signal processing for continuous analyte sensor
US11638541B2 (en) 2003-12-09 2023-05-02 Dexconi, Inc. Signal processing for continuous analyte sensor
US9750441B2 (en) 2003-12-09 2017-09-05 Dexcom, Inc. Signal processing for continuous analyte sensor
US9351668B2 (en) 2003-12-09 2016-05-31 Dexcom, Inc. Signal processing for continuous analyte sensor
US8469886B2 (en) 2003-12-09 2013-06-25 Dexcom, Inc. Signal processing for continuous analyte sensor
US8747315B2 (en) 2003-12-09 2014-06-10 Dexcom. Inc. Signal processing for continuous analyte sensor
US9498155B2 (en) 2003-12-09 2016-11-22 Dexcom, Inc. Signal processing for continuous analyte sensor
US8657745B2 (en) 2003-12-09 2014-02-25 Dexcom, Inc. Signal processing for continuous analyte sensor
US10898113B2 (en) 2003-12-09 2021-01-26 Dexcom, Inc. Signal processing for continuous analyte sensor
US8233958B2 (en) 2003-12-09 2012-07-31 Dexcom, Inc. Signal processing for continuous analyte sensor
US9420965B2 (en) 2003-12-09 2016-08-23 Dexcom, Inc. Signal processing for continuous analyte sensor
US8216139B2 (en) 2003-12-09 2012-07-10 Dexcom, Inc. Signal processing for continuous analyte sensor
US8290561B2 (en) 2003-12-09 2012-10-16 Dexcom, Inc. Signal processing for continuous analyte sensor
US8251906B2 (en) 2003-12-09 2012-08-28 Dexcom, Inc. Signal processing for continuous analyte sensor
US8257259B2 (en) 2003-12-09 2012-09-04 Dexcom, Inc. Signal processing for continuous analyte sensor
US8282549B2 (en) 2003-12-09 2012-10-09 Dexcom, Inc. Signal processing for continuous analyte sensor
US9107623B2 (en) 2003-12-09 2015-08-18 Dexcom, Inc. Signal processing for continuous analyte sensor
US8374667B2 (en) 2003-12-09 2013-02-12 Dexcom, Inc. Signal processing for continuous analyte sensor
US9364173B2 (en) 2003-12-09 2016-06-14 Dexcom, Inc. Signal processing for continuous analyte sensor
US8265725B2 (en) 2003-12-09 2012-09-11 Dexcom, Inc. Signal processing for continuous analyte sensor
US8801610B2 (en) 2003-12-09 2014-08-12 Dexcom, Inc. Signal processing for continuous analyte sensor
US20070020299A1 (en) * 2003-12-31 2007-01-25 Pipkin James D Inhalant formulation containing sulfoalkyl ether cyclodextrin and corticosteroid
US10159752B2 (en) 2003-12-31 2018-12-25 Cydex Pharmaceuticals, Inc. Inhalant formulation containing sulfoalkyl ether cyclodextrin and corticosteroid
US10207008B2 (en) 2003-12-31 2019-02-19 Cydex Pharmaceuticals, Inc. Inhalant formulation containing sulfoalkyl ether cyclodextrin and corticosteroid
US10799599B2 (en) 2003-12-31 2020-10-13 Cydex Pharmaceuticals, Inc. Inhalant formulation containing sulfoalkyl ether cyclodextrin and corticosteroid
EP1732512A4 (en) * 2003-12-31 2008-07-23 Cydex Inc INHALATION FORMULATION CONTAINING SULFOALKYL ETHER CYCLODEXTRIN AND CORTICOSTEROID
US9827324B2 (en) 2003-12-31 2017-11-28 Cydex Pharmaceuticals, Inc. Inhalant formulation containing sulfoalkyl ether cyclodextrin and corticosteroid
US20070202054A1 (en) * 2003-12-31 2007-08-30 Pipkin James D Inhalant Formulation Containing Sulfoalkyl Ether Cyclodextrin and Corticosteroid
EP1718276A4 (en) * 2003-12-31 2008-07-23 Cydex Inc Inhalant formulation containing sulfoalkylether cyclodextrin and corticosteroid prepared from a unit dose suspension
US20070020196A1 (en) * 2003-12-31 2007-01-25 Pipkin James D Inhalant formulation containing sulfoalkyl ether cyclodextrin and corticosteroid prepared from a unit dose suspension
US7637868B2 (en) 2004-01-12 2009-12-29 Dexcom, Inc. Composite material for implantable device
US8721585B2 (en) 2004-02-26 2014-05-13 Dex Com, Inc. Integrated delivery device for continuous glucose sensor
US10835672B2 (en) 2004-02-26 2020-11-17 Dexcom, Inc. Integrated insulin delivery system with continuous glucose sensor
US7591801B2 (en) * 2004-02-26 2009-09-22 Dexcom, Inc. Integrated delivery device for continuous glucose sensor
US8882741B2 (en) 2004-02-26 2014-11-11 Dexcom, Inc. Integrated delivery device for continuous glucose sensor
US12115357B2 (en) 2004-02-26 2024-10-15 Dexcom, Inc. Integrated delivery device for continuous glucose sensor
US8808228B2 (en) 2004-02-26 2014-08-19 Dexcom, Inc. Integrated medicament delivery device for use with continuous analyte sensor
US10278580B2 (en) 2004-02-26 2019-05-07 Dexcom, Inc. Integrated medicament delivery device for use with continuous analyte sensor
US8920401B2 (en) 2004-02-26 2014-12-30 Dexcom, Inc. Integrated delivery device for continuous glucose sensor
US9155843B2 (en) 2004-02-26 2015-10-13 Dexcom, Inc. Integrated delivery device for continuous glucose sensor
US8926585B2 (en) 2004-02-26 2015-01-06 Dexcom, Inc. Integrated delivery device for continuous glucose sensor
US11246990B2 (en) 2004-02-26 2022-02-15 Dexcom, Inc. Integrated delivery device for continuous glucose sensor
US12102410B2 (en) 2004-02-26 2024-10-01 Dexcom, Inc Integrated medicament delivery device for use with continuous analyte sensor
US9937293B2 (en) 2004-02-26 2018-04-10 Dexcom, Inc. Integrated delivery device for continuous glucose sensor
US9050413B2 (en) 2004-02-26 2015-06-09 Dexcom, Inc. Integrated delivery device for continuous glucose sensor
US8460231B2 (en) 2004-02-26 2013-06-11 Dexcom, Inc. Integrated delivery device for continuous glucose sensor
US7976492B2 (en) 2004-02-26 2011-07-12 Dexcom, Inc. Integrated delivery device for continuous glucose sensor
US10966609B2 (en) 2004-02-26 2021-04-06 Dexcom, Inc. Integrated medicament delivery device for use with continuous analyte sensor
US12226617B2 (en) 2004-02-26 2025-02-18 Dexcom, Inc. Integrated delivery device for continuous glucose sensor
US9833143B2 (en) 2004-05-03 2017-12-05 Dexcom, Inc. Transcutaneous analyte sensor
US8792955B2 (en) 2004-05-03 2014-07-29 Dexcom, Inc. Transcutaneous analyte sensor
US7657297B2 (en) 2004-05-03 2010-02-02 Dexcom, Inc. Implantable analyte sensor
US10327638B2 (en) 2004-05-03 2019-06-25 Dexcom, Inc. Transcutaneous analyte sensor
US8333197B2 (en) 2004-06-03 2012-12-18 Alexza Pharmaceuticals, Inc. Multiple dose condensation aerosol devices and methods of forming condensation aerosols
US7540286B2 (en) 2004-06-03 2009-06-02 Alexza Pharmaceuticals, Inc. Multiple dose condensation aerosol devices and methods of forming condensation aerosols
US8231531B2 (en) 2004-07-13 2012-07-31 Dexcom, Inc. Analyte sensor
US10918314B2 (en) 2004-07-13 2021-02-16 Dexcom, Inc. Analyte sensor
US8571625B2 (en) 2004-07-13 2013-10-29 Dexcom, Inc. Transcutaneous analyte sensor
US10709363B2 (en) 2004-07-13 2020-07-14 Dexcom, Inc. Analyte sensor
US10709362B2 (en) 2004-07-13 2020-07-14 Dexcom, Inc. Analyte sensor
US8565848B2 (en) 2004-07-13 2013-10-22 Dexcom, Inc. Transcutaneous analyte sensor
US10722152B2 (en) 2004-07-13 2020-07-28 Dexcom, Inc. Analyte sensor
US11883164B2 (en) 2004-07-13 2024-01-30 Dexcom, Inc. System and methods for processing analyte sensor data for sensor calibration
US10524703B2 (en) 2004-07-13 2020-01-07 Dexcom, Inc. Transcutaneous analyte sensor
US10799159B2 (en) 2004-07-13 2020-10-13 Dexcom, Inc. Analyte sensor
US10799158B2 (en) 2004-07-13 2020-10-13 Dexcom, Inc. Analyte sensor
US8565849B2 (en) 2004-07-13 2013-10-22 Dexcom, Inc. Transcutaneous analyte sensor
US9060742B2 (en) 2004-07-13 2015-06-23 Dexcom, Inc. Transcutaneous analyte sensor
US8825127B2 (en) 2004-07-13 2014-09-02 Dexcom, Inc. Transcutaneous analyte sensor
US9055901B2 (en) 2004-07-13 2015-06-16 Dexcom, Inc. Transcutaneous analyte sensor
US8812072B2 (en) 2004-07-13 2014-08-19 Dexcom, Inc. Transcutaneous medical device with variable stiffness
US8548551B2 (en) 2004-07-13 2013-10-01 Dexcom, Inc. Transcutaneous analyte sensor
US8515516B2 (en) 2004-07-13 2013-08-20 Dexcom, Inc. Transcutaneous analyte sensor
US8483791B2 (en) 2004-07-13 2013-07-09 Dexcom, Inc. Transcutaneous analyte sensor
US10813576B2 (en) 2004-07-13 2020-10-27 Dexcom, Inc. Analyte sensor
US9044199B2 (en) 2004-07-13 2015-06-02 Dexcom, Inc. Transcutaneous analyte sensor
US7640048B2 (en) 2004-07-13 2009-12-29 Dexcom, Inc. Analyte sensor
US10827956B2 (en) 2004-07-13 2020-11-10 Dexcom, Inc. Analyte sensor
US11064917B2 (en) 2004-07-13 2021-07-20 Dexcom, Inc. Analyte sensor
US8463350B2 (en) 2004-07-13 2013-06-11 Dexcom, Inc. Transcutaneous analyte sensor
US7783333B2 (en) 2004-07-13 2010-08-24 Dexcom, Inc. Transcutaneous medical device with variable stiffness
US11045120B2 (en) 2004-07-13 2021-06-29 Dexcom, Inc. Analyte sensor
US9414777B2 (en) 2004-07-13 2016-08-16 Dexcom, Inc. Transcutaneous analyte sensor
US8792953B2 (en) 2004-07-13 2014-07-29 Dexcom, Inc. Transcutaneous analyte sensor
US9986942B2 (en) 2004-07-13 2018-06-05 Dexcom, Inc. Analyte sensor
US8290560B2 (en) 2004-07-13 2012-10-16 Dexcom, Inc. Transcutaneous analyte sensor
US11026605B1 (en) 2004-07-13 2021-06-08 Dexcom, Inc. Analyte sensor
US8280475B2 (en) 2004-07-13 2012-10-02 Dexcom, Inc. Transcutaneous analyte sensor
US8858434B2 (en) 2004-07-13 2014-10-14 Dexcom, Inc. Transcutaneous analyte sensor
US8792954B2 (en) 2004-07-13 2014-07-29 Dexcom, Inc. Transcutaneous analyte sensor
US10993641B2 (en) 2004-07-13 2021-05-04 Dexcom, Inc. Analyte sensor
US8750955B2 (en) 2004-07-13 2014-06-10 Dexcom, Inc. Analyte sensor
US10993642B2 (en) 2004-07-13 2021-05-04 Dexcom, Inc. Analyte sensor
US10980452B2 (en) 2004-07-13 2021-04-20 Dexcom, Inc. Analyte sensor
US8170803B2 (en) 2004-07-13 2012-05-01 Dexcom, Inc. Transcutaneous analyte sensor
US8663109B2 (en) 2004-07-13 2014-03-04 Dexcom, Inc. Transcutaneous analyte sensor
US7857760B2 (en) 2004-07-13 2010-12-28 Dexcom, Inc. Analyte sensor
US10932700B2 (en) 2004-07-13 2021-03-02 Dexcom, Inc. Analyte sensor
US8690775B2 (en) 2004-07-13 2014-04-08 Dexcom, Inc. Transcutaneous analyte sensor
US7949381B2 (en) 2004-07-13 2011-05-24 Dexcom, Inc. Transcutaneous analyte sensor
US8731630B2 (en) 2004-07-13 2014-05-20 Dexcom, Inc. Transcutaneous analyte sensor
US10918315B2 (en) 2004-07-13 2021-02-16 Dexcom, Inc. Analyte sensor
US7885697B2 (en) 2004-07-13 2011-02-08 Dexcom, Inc. Transcutaneous analyte sensor
US9801572B2 (en) 2004-07-13 2017-10-31 Dexcom, Inc. Transcutaneous analyte sensor
US9775543B2 (en) 2004-07-13 2017-10-03 Dexcom, Inc. Transcutaneous analyte sensor
US10918313B2 (en) 2004-07-13 2021-02-16 Dexcom, Inc. Analyte sensor
US7905833B2 (en) 2004-07-13 2011-03-15 Dexcom, Inc. Transcutaneous analyte sensor
US7899511B2 (en) 2004-07-13 2011-03-01 Dexcom, Inc. Low oxygen in vivo analyte sensor
US7581540B2 (en) 2004-08-12 2009-09-01 Alexza Pharmaceuticals, Inc. Aerosol drug delivery device incorporating percussively activated heat packages
US11051726B2 (en) 2005-03-10 2021-07-06 Dexcom, Inc. System and methods for processing analyte sensor data for sensor calibration
US10918317B2 (en) 2005-03-10 2021-02-16 Dexcom, Inc. System and methods for processing analyte sensor data for sensor calibration
US8579816B2 (en) 2005-03-10 2013-11-12 Dexcom, Inc. System and methods for processing analyte sensor data for sensor calibration
US10918316B2 (en) 2005-03-10 2021-02-16 Dexcom, Inc. System and methods for processing analyte sensor data for sensor calibration
US10925524B2 (en) 2005-03-10 2021-02-23 Dexcom, Inc. System and methods for processing analyte sensor data for sensor calibration
US10898114B2 (en) 2005-03-10 2021-01-26 Dexcom, Inc. System and methods for processing analyte sensor data for sensor calibration
US10709364B2 (en) 2005-03-10 2020-07-14 Dexcom, Inc. System and methods for processing analyte sensor data for sensor calibration
US9078608B2 (en) 2005-03-10 2015-07-14 Dexcom, Inc. System and methods for processing analyte sensor data for sensor calibration
US9918668B2 (en) 2005-03-10 2018-03-20 Dexcom, Inc. System and methods for processing analyte sensor data for sensor calibration
US11000213B2 (en) 2005-03-10 2021-05-11 Dexcom, Inc. System and methods for processing analyte sensor data for sensor calibration
US8611978B2 (en) 2005-03-10 2013-12-17 Dexcom, Inc. System and methods for processing analyte sensor data for sensor calibration
US10856787B2 (en) 2005-03-10 2020-12-08 Dexcom, Inc. System and methods for processing analyte sensor data for sensor calibration
US10743801B2 (en) 2005-03-10 2020-08-18 Dexcom, Inc. System and methods for processing analyte sensor data for sensor calibration
US10716498B2 (en) 2005-03-10 2020-07-21 Dexcom, Inc. System and methods for processing analyte sensor data for sensor calibration
US10918318B2 (en) 2005-03-10 2021-02-16 Dexcom, Inc. System and methods for processing analyte sensor data for sensor calibration
US10617336B2 (en) 2005-03-10 2020-04-14 Dexcom, Inc. System and methods for processing analyte sensor data for sensor calibration
US10624539B2 (en) 2005-03-10 2020-04-21 Dexcom, Inc. Transcutaneous analyte sensor
US10610102B2 (en) 2005-03-10 2020-04-07 Dexcom, Inc. Transcutaneous analyte sensor
US10610136B2 (en) 2005-03-10 2020-04-07 Dexcom, Inc. System and methods for processing analyte sensor data for sensor calibration
US7920906B2 (en) 2005-03-10 2011-04-05 Dexcom, Inc. System and methods for processing analyte sensor data for sensor calibration
US9314196B2 (en) 2005-03-10 2016-04-19 Dexcom, Inc. System and methods for processing analyte sensor data for sensor calibration
US10610135B2 (en) 2005-03-10 2020-04-07 Dexcom, Inc. System and methods for processing analyte sensor data for sensor calibration
US9220449B2 (en) 2005-03-10 2015-12-29 Dexcom, Inc. System and methods for processing analyte sensor data for sensor calibration
US8560037B2 (en) 2005-03-10 2013-10-15 Dexcom, Inc. System and methods for processing analyte sensor data for sensor calibration
US10610137B2 (en) 2005-03-10 2020-04-07 Dexcom, Inc. System and methods for processing analyte sensor data for sensor calibration
US10610103B2 (en) 2005-06-21 2020-04-07 Dexcom, Inc. Transcutaneous analyte sensor
US10813577B2 (en) 2005-06-21 2020-10-27 Dexcom, Inc. Analyte sensor
US10709332B2 (en) 2005-06-21 2020-07-14 Dexcom, Inc. Transcutaneous analyte sensor
US8367734B1 (en) 2005-08-11 2013-02-05 Amphastar Pharmaceuticals Inc. Stable epinephrine suspension formulation with high inhalation delivery efficiency
US9326716B2 (en) 2005-11-01 2016-05-03 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
US11911151B1 (en) 2005-11-01 2024-02-27 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
US11399748B2 (en) 2005-11-01 2022-08-02 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
US11363975B2 (en) 2005-11-01 2022-06-21 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
US11272867B2 (en) 2005-11-01 2022-03-15 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
US8915850B2 (en) 2005-11-01 2014-12-23 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
US10231654B2 (en) 2005-11-01 2019-03-19 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
US9078607B2 (en) 2005-11-01 2015-07-14 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
US8920319B2 (en) 2005-11-01 2014-12-30 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
US10201301B2 (en) 2005-11-01 2019-02-12 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
US11103165B2 (en) 2005-11-01 2021-08-31 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
US10952652B2 (en) 2005-11-01 2021-03-23 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
US20070249572A1 (en) * 2005-12-20 2007-10-25 Verus Pharmaceuticals, Inc. Systems and methods for the delivery of corticosteroids
US20070160542A1 (en) * 2005-12-20 2007-07-12 Verus Pharmaceuticals, Inc. Methods and systems for the delivery of corticosteroids having an enhanced pharmacokinetic profile
US20070178050A1 (en) * 2005-12-20 2007-08-02 Verus Pharmaceuticals, Inc. Methods and systems for the delivery of corticosteroids having an increased lung depositon
US20070178049A1 (en) * 2005-12-20 2007-08-02 Verus Pharmaceuticals, Inc. Systems and methods for the delivery of corticosteroids having an enhanced pharmacokinetic profile
US20070185066A1 (en) * 2005-12-20 2007-08-09 Verus Pharmaceuticals, Inc. Systems and methods for the delivery of corticosteroids
US20070197486A1 (en) * 2005-12-20 2007-08-23 Verus Pharmaceuticals, Inc. Methods and systems for the delivery of corticosteroids
US20070197487A1 (en) * 2005-12-20 2007-08-23 Verus Pharmaceuticals, Inc. Systems and methods for the delivery of corticosteroids having an increased lung deposition
US10265000B2 (en) 2006-01-17 2019-04-23 Dexcom, Inc. Low oxygen in vivo analyte sensor
US11596332B2 (en) 2006-01-17 2023-03-07 Dexcom, Inc. Low oxygen in vivo analyte sensor
US11191458B2 (en) 2006-01-17 2021-12-07 Dexcom, Inc. Low oxygen in vivo analyte sensor
US9757061B2 (en) 2006-01-17 2017-09-12 Dexcom, Inc. Low oxygen in vivo analyte sensor
US9724028B2 (en) 2006-02-22 2017-08-08 Dexcom, Inc. Analyte sensor
US7920907B2 (en) 2006-06-07 2011-04-05 Abbott Diabetes Care Inc. Analyte monitoring system and method
US20090191134A1 (en) * 2006-06-12 2009-07-30 Medispray Laboratoriespvt. Ltd. Stable aerosol pharmaceutical formulations
US11432772B2 (en) 2006-08-02 2022-09-06 Dexcom, Inc. Systems and methods for replacing signal artifacts in a glucose sensor data stream
US11382539B2 (en) 2006-10-04 2022-07-12 Dexcom, Inc. Analyte sensor
US9451908B2 (en) 2006-10-04 2016-09-27 Dexcom, Inc. Analyte sensor
US10349873B2 (en) 2006-10-04 2019-07-16 Dexcom, Inc. Analyte sensor
US11399745B2 (en) 2006-10-04 2022-08-02 Dexcom, Inc. Dual electrode system for a continuous analyte sensor
US8119639B2 (en) 2007-02-11 2012-02-21 Map Pharmaceuticals, Inc. Method of therapeutic administration of DHE to enable rapid relief of migraine while minimizing side effect profile
US8148377B2 (en) 2007-02-11 2012-04-03 Map Pharmaceuticals, Inc. Method of therapeutic administration of DHE to enable rapid relief of migraine while minimizing side effect profile
US20080287451A1 (en) * 2007-02-11 2008-11-20 Cook Robert O Method of therapeutic administration of DHE to enable rapid relief of migraine while minimizing side effect profile
US10172853B2 (en) 2007-02-11 2019-01-08 Map Pharmaceuticals, Inc. Method of therapeutic administration of DHE to enable rapid relief of migraine while minimizing side effect profile
US7994197B2 (en) 2007-02-11 2011-08-09 Map Pharmaceuticals, Inc. Method of therapeutic administration of DHE to enable rapid relief of migraine while minimizing side effect profile
US9833451B2 (en) 2007-02-11 2017-12-05 Map Pharmaceuticals, Inc. Method of therapeutic administration of DHE to enable rapid relief of migraine while minimizing side effect profile
US12138383B2 (en) 2007-03-09 2024-11-12 Alexza Pharmaceuticals, Inc. Heating unit for use in a drug delivery device
US11642473B2 (en) 2007-03-09 2023-05-09 Alexza Pharmaceuticals, Inc. Heating unit for use in a drug delivery device
US8562558B2 (en) 2007-06-08 2013-10-22 Dexcom, Inc. Integrated medicament delivery device for use with continuous analyte sensor
US12394120B2 (en) 2007-06-08 2025-08-19 Dexcom, Inc. Integrated medicament delivery device for use with continuous analyte sensor
US9741139B2 (en) 2007-06-08 2017-08-22 Dexcom, Inc. Integrated medicament delivery device for use with continuous analyte sensor
US10403012B2 (en) 2007-06-08 2019-09-03 Dexcom, Inc. Integrated medicament delivery device for use with continuous analyte sensor
US11373347B2 (en) 2007-06-08 2022-06-28 Dexcom, Inc. Integrated medicament delivery device for use with continuous analyte sensor
US12370352B2 (en) 2007-06-28 2025-07-29 Cydex Pharmaceuticals, Inc. Nasal and ophthalmic delivery of aqueous corticosteroid solutions
US9668682B2 (en) 2007-09-13 2017-06-06 Dexcom, Inc. Transcutaneous analyte sensor
US9451910B2 (en) 2007-09-13 2016-09-27 Dexcom, Inc. Transcutaneous analyte sensor
US11672422B2 (en) 2007-09-13 2023-06-13 Dexcom, Inc. Transcutaneous analyte sensor
US12016648B2 (en) 2007-09-13 2024-06-25 Dexcom, Inc. Transcutaneous analyte sensor
US12246166B2 (en) 2007-10-09 2025-03-11 Dexcom, Inc. Integrated insulin delivery system with continuous glucose sensor
US12397110B2 (en) 2007-10-09 2025-08-26 Dexcom, Inc. Integrated insulin delivery system with continuous glucose sensor
US11744943B2 (en) 2007-10-09 2023-09-05 Dexcom, Inc. Integrated insulin delivery system with continuous glucose sensor
US12397113B2 (en) 2007-10-09 2025-08-26 Dexcom, Inc. Integrated insulin delivery system with continuous glucose sensor
US10653835B2 (en) 2007-10-09 2020-05-19 Dexcom, Inc. Integrated insulin delivery system with continuous glucose sensor
US11160926B1 (en) 2007-10-09 2021-11-02 Dexcom, Inc. Pre-connected analyte sensors
US20120111324A1 (en) * 2007-10-22 2012-05-10 Board Of Regents, The University Of Texas System Dry Powder Drug Delivery Formulations, Methods of Use, and Devices Therefore
US8597616B2 (en) * 2007-10-22 2013-12-03 Board Of Regents Of The University Of Texas System Dry powder drug delivery formulations, methods of use, and devices therefore
US11272869B2 (en) 2007-10-25 2022-03-15 Dexcom, Inc. Systems and methods for processing sensor data
US8417312B2 (en) 2007-10-25 2013-04-09 Dexcom, Inc. Systems and methods for processing sensor data
US10182751B2 (en) 2007-10-25 2019-01-22 Dexcom, Inc. Systems and methods for processing sensor data
US9717449B2 (en) 2007-10-25 2017-08-01 Dexcom, Inc. Systems and methods for processing sensor data
US20090140851A1 (en) * 2007-12-04 2009-06-04 Nortel Networks Limited Systems and methods for facilitating a first response mission at an incident scene using patient monitoring
US8290559B2 (en) 2007-12-17 2012-10-16 Dexcom, Inc. Systems and methods for processing sensor data
US11342058B2 (en) 2007-12-17 2022-05-24 Dexcom, Inc. Systems and methods for processing sensor data
US9135402B2 (en) 2007-12-17 2015-09-15 Dexcom, Inc. Systems and methods for processing sensor data
US12165757B2 (en) 2007-12-17 2024-12-10 Dexcom, Inc. Systems and methods for processing sensor data
US9339238B2 (en) 2007-12-17 2016-05-17 Dexcom, Inc. Systems and methods for processing sensor data
US9839395B2 (en) 2007-12-17 2017-12-12 Dexcom, Inc. Systems and methods for processing sensor data
US9901307B2 (en) 2007-12-17 2018-02-27 Dexcom, Inc. Systems and methods for processing sensor data
US9149234B2 (en) 2007-12-17 2015-10-06 Dexcom, Inc. Systems and methods for processing sensor data
US10827980B2 (en) 2007-12-17 2020-11-10 Dexcom, Inc. Systems and methods for processing sensor data
US10506982B2 (en) 2007-12-17 2019-12-17 Dexcom, Inc. Systems and methods for processing sensor data
US9149233B2 (en) 2007-12-17 2015-10-06 Dexcom, Inc. Systems and methods for processing sensor data
US9143569B2 (en) 2008-02-21 2015-09-22 Dexcom, Inc. Systems and methods for processing, transmitting and displaying sensor data
US9020572B2 (en) 2008-02-21 2015-04-28 Dexcom, Inc. Systems and methods for processing, transmitting and displaying sensor data
US8229535B2 (en) 2008-02-21 2012-07-24 Dexcom, Inc. Systems and methods for blood glucose monitoring and alert delivery
US8591455B2 (en) 2008-02-21 2013-11-26 Dexcom, Inc. Systems and methods for customizing delivery of sensor data
US11102306B2 (en) 2008-02-21 2021-08-24 Dexcom, Inc. Systems and methods for processing, transmitting and displaying sensor data
US11896374B2 (en) 2008-03-25 2024-02-13 Dexcom, Inc. Analyte sensor
US8396528B2 (en) 2008-03-25 2013-03-12 Dexcom, Inc. Analyte sensor
US10602968B2 (en) 2008-03-25 2020-03-31 Dexcom, Inc. Analyte sensor
US9339222B2 (en) 2008-09-19 2016-05-17 Dexcom, Inc. Particle-containing membrane and particulate electrode for analyte sensors
US10028683B2 (en) 2008-09-19 2018-07-24 Dexcom, Inc. Particle-containing membrane and particulate electrode for analyte sensors
US8560039B2 (en) 2008-09-19 2013-10-15 Dexcom, Inc. Particle-containing membrane and particulate electrode for analyte sensors
US11918354B2 (en) 2008-09-19 2024-03-05 Dexcom, Inc. Particle-containing membrane and particulate electrode for analyte sensors
US10561352B2 (en) 2008-09-19 2020-02-18 Dexcom, Inc. Particle-containing membrane and particulate electrode for analyte sensors
US10028684B2 (en) 2008-09-19 2018-07-24 Dexcom, Inc. Particle-containing membrane and particulate electrode for analyte sensors
US10980461B2 (en) 2008-11-07 2021-04-20 Dexcom, Inc. Advanced analyte sensor calibration and error detection
US10537678B2 (en) 2009-03-27 2020-01-21 Dexcom, Inc. Methods and systems for promoting glucose management
US10675405B2 (en) 2009-03-27 2020-06-09 Dexcom, Inc. Methods and systems for simulating glucose response to simulated actions
US10610642B2 (en) 2009-03-27 2020-04-07 Dexcom, Inc. Methods and systems for promoting glucose management
US9446194B2 (en) 2009-03-27 2016-09-20 Dexcom, Inc. Methods and systems for promoting glucose management
US11350862B2 (en) 2017-10-24 2022-06-07 Dexcom, Inc. Pre-connected analyte sensors
US12150250B2 (en) 2017-10-24 2024-11-19 Dexcom, Inc. Pre-connected analyte sensors
US11943876B2 (en) 2017-10-24 2024-03-26 Dexcom, Inc. Pre-connected analyte sensors
US11331022B2 (en) 2017-10-24 2022-05-17 Dexcom, Inc. Pre-connected analyte sensors
US11706876B2 (en) 2017-10-24 2023-07-18 Dexcom, Inc. Pre-connected analyte sensors
US11382540B2 (en) 2017-10-24 2022-07-12 Dexcom, Inc. Pre-connected analyte sensors
US12214119B2 (en) 2018-02-02 2025-02-04 Alexza Pharmaceuticals, Inc. Electrical condensation aerosol device
US12214118B2 (en) 2018-02-02 2025-02-04 Alexza Pharmaceuticals, Inc. Electrical condensation aerosol device

Also Published As

Publication number Publication date
BE629985A (en)
DE1492015A1 (en) 1969-03-06
GB1018125A (en) 1966-01-26
NL289785A (en)

Similar Documents

Publication Publication Date Title
US3219533A (en) Aerosol solid medicament in propellant and low-level ethanol avoiding higher-level ethanol dispersed-solid reflocculation
US9446054B2 (en) Pharmaceutical products and composition comprising specific anticholinergic agents, β-2 agonists and corticosteroids
JP3056784B2 (en) Aerosol pharmaceutical preparation
EP0416951B1 (en) Medicaments comprising salmeterol and fluticason
EP0731688B1 (en) Aerosol drug formulations for use with non-cfc propellants
KR100940752B1 (en) Novel pharmaceutical compositions based on tiotropium salts and salmeterol salts
US5208226A (en) Medicaments
CA2024872C (en) Medicaments
JP2004500429A (en) Pharmaceutical combinations containing tiotropium and rofleponide
JPH05963A (en) Polypeptide composition
AU2021200503B2 (en) Composition comprising at least one dry powder obtained by spray drying to increase the stability of the formulation
TW200524615A (en) Aqueous suspensions of ciclesonide for nebulisation
US3282781A (en) Inhalant compositions
GB2235627A (en) Inhalation medicaments
PT92188B (en) A process for the preparation of a water-soluble solution comprising chromogenic acid and salbutamol
EP0285246B1 (en) Calcium-4,6-dioxo-4h-pyrano[3,2-g]-quinoline-2,8-dicarboxylate derivative, methods for its preparation and compositions containing it
AU2004262901B2 (en) Combination of an anticholinergic and a steroid and its use to treat respiratory disorders by inhalation
JP2004500431A (en) Pharmaceutical composition comprising (R, R) -formoterol and rofleponide
ZA200501703B (en) Pharmaceutical products and compositions comprising specific anticholinergic agents, beta-2-agonists and corti-costeroids.
MXPA99011676A (en) New combination of antiasthma medicaments
MXPA98004357A (en) New combination